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ABSTRACT
Asthma, a chronic respiratory condition, is common worldwide with no cure and
limited effective prevention strategies. It is well recognized that asthma has a
multifaceted etiology, though many of the underlying mechanisms involved in asthma
development, persistence and remission are still convoluted. Epigenetic mechanisms,
such as DNA methylation, regulate gene-expression but are not related to changes in the
actual DNA sequence. Recently, differential patterns of DNA methylation within many
genes have been associated with asthma, particularly within genes involved in the
differentiation of pro-inflammatory T-helper 2 (Th2) cells. DNA methylation patterns
within less known biologic pathways undoubtedly are involved in asthma pathogenesis as
well. The purpose of this dissertation was three-fold. First, we explored whether genetic
and epigenetic variations within Th2-genes differed among persons with different
phenotypic presentations of wheeze illnesses. Second, we conducted an epigenome-wide
association study (EWAS) to identify novel DNA methylation loci associated with
asthma. Last, we conducted a follow-up study of our top EWAS findings, to investigate
whether the expression of the associated genes were predictive of infant wheeze.
We found that DNA-M within GATA3 and IL4 varied based on different wheezeillness phenotypes, suggesting that Th2-genes are under differential epigenetic regulation
for different presentations of asthma. We also identified nine novel DNA methylation
loci (cg25578728 in CHD7, cg16658191 in HK1, cg00100703 in UNC45B, cg07948085
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[intergenic], cg04359558 in LITAF, cg20417424 in ST6GALNAC5, cg19974715
[intergenic], cg01046943 in NUP210 and cg14727512 in DGCR14) associated with
asthma at age 18. For two of those genes (HK1 and LITAF), expression levels in cord
blood were predictive of infant wheeze. Interestingly, the observed methylation and
expression patterns of HK1 and LITAF could be consistent with increased resistance to
apoptotic signaling. Apoptotic-resistance among pro-inflammatory cells can increase the
duration of an inflammatory response and is affiliated with asthmatic pathophysiology.
Thus we may have identified under-studied genes and their epigenetic regulation, which
could play important roles in asthma pathophysiology. These genes may offer new
insights into the etiology of asthma, be investigated as potential targets for therapy, or be
considered for inclusion in algorithms used to predict early-life wheeze and later-life
asthma.
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CHAPTER 1
BACKGROUND ON ASTHMA AND EPIGENETICS
1.1 Asthma Background:
Asthma is a chronic respiratory disease often defined by reversible airway
obstruction, wheeze, bronchial hyper-responsiveness, and inflammation1. Many
molecular pathways influence the recruitment and the activity of different immune cells
during asthmatic symptoms, thus leading to heterogeneity in what triggers the symptoms
to occur as well as their severity and responsiveness to treatments1. Given the vast
heterogeneity in asthma, many possible phenotypes have been described. In fact, it is
unclear whether asthma is a single disease with multiple presentations, or instead several
different diseases, all with the common symptom of reversible restriction of the airways2.
Some characteristics allow for the distinction of common asthma sub-types. For
instance, those whose asthma symptoms are triggered by allergens (ie. pollen, cockroach,
mold, and dust mite) are often distinguished from those whose symptoms arise with no
apparent allergic triggers as “extrinsic” vs. “intrinsic” types1. Interestingly, there is also
some overlap in triggers for both extrinsic and intrinsic asthma. Both may be
symptomatic to exercise, cold air, and inhaled irritants3, suggesting some overlap in
common underlying mechanisms leading to exacerbations. Intrinsic asthma appears to be
more severe, as positive skin prick tests (SPTs) are less common in severe asthma
compared to less-severe asthma and extrinsic asthma tends to have an earlier onset than
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intrinsic3 but is more transient and responds better to treatment with corticosteroids1. The
exact distribution of extrinsic vs intrinsic asthma is unclear, although the majority of
asthmatics tend have the extrinsic characteristics of allergic sensitization such as high
serum immunoglobulin (Ig)E and/or positive SPT results3.
Aside from differences in triggers and allergic hypersensitivity characterized by
extrinsic vs. intrinsic phenotypes, asthmatics also may differ in many other characteristics
important in understanding disease progression such as age of symptomatic onset,
comorbidity with other allergic diseases (eczema and/or rhinitis), overall lung function,
responsiveness to inhaled corticosteroids (ICS) and other treatments, as well as markers
of airway eosinophilia such as fractional-exhaled nitric oxide (FeNO)4. These measures
inform us about the pathophysiology of asthma, but there is also heterogeneity in the
morbidity associated with asthma, such as frequency and severity of wheeze attacks, as
well as when wheeze disturbs sleep, limits speech, or limits exercise5. Thus, it is of great
importance to identify risk factors for the development, persistence, remission, and
relapse of different asthmatic phenotypes6.
Asthma Epidemiology:
The prevalence of asthma varies by many demographic characteristics: age, sex,
race, and socio-economic status (SES). The Centers for Disease Control and Prevention
(CDC) showed that between 2008 and 2010, the average annual prevalence of asthma in
the US tended to be higher in children than in adults, higher in females than males, higher
in blacks compared to other races, higher among Hispanics compared to non-Hispanic,
and higher among those in lower socio-economic groups7. The sex difference in asthma is
age-dependent. Males typically have higher incidence and prevalence from birth through
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puberty, then tend to exhibit higher rates of remission, whereas females tend to have
higher incidence and prevalence as young adults6. Asthma severity parallels the same
sex-age-dependent pattern with males having more severe asthma in childhood and
females having more severe asthma in adulthood6.
Asthma, as well as other allergic diseases, have been increasing in prevalence
worldwide for decades and are some of the most common sources of chronic health
issues8,9, the Global Asthma Network estimates that as many as 334 million people are
affected by asthma10. Despite increasing global prevalence, region specific trends indicate
that asthma prevalence in many high-income countries has recently peaked, whereas
prevalence in low- or middle-income countries is still on the rise11. Despite the recent
decline in incidence, mortality, and health care utilization, the prevalence of asthma
symptoms remains high in high-income countries, ranging from 8.6-14.4%11. A recent
study in the UK found that new diagnoses of asthma have plateaued, but that the lifetimeprevalence is still increasing12. In the US, the prevalence of asthma, which was only 3%
in the 1980s, steadily grew to 8.4% by 20107. The American Lung Association reports
that approximately 25.9 million people in the US had asthma in 2011 and an estimated
13.2 million (51% of those with asthma) had at least one asthma attack within the 12
months prior to the survey13. Asthma also generates a substantial burden on health-care
systems and was responsible for 10.6 million physician office visits and 2.1 million
emergency room visits in 2010 in the US alone13.
The prevalence of asthma symptoms was highly variable in low- or middleincome regions, but in many cases was higher than that of high-income countries, ranging
from 6.8-21.7%11. In fact, the majority of persons affected by asthma are living in low- or
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middle- income countries10. The increasing incidence of asthma in low- or middleincome countries appears to be related to urbanization, which is expected to continue to
expand in most of these countries11. So it is possible that the increasing incidence of
asthma in low- and middle-income countries will actually accelerate in the years to come,
further increasing the already heavy global burden of asthma. High prevalence worldwide
and increasing prevalence in low- and middle- income countries means that millions of
people will continue to chronically medicate in order to prevent or relieve asthma
symptoms since there is no cure for this disease14.
Asthma Etiology:
Due to the increasing prevalence worldwide, research into asthmatic risk factors
and underlying mechanisms of disease received substantial focus. Yet, the etiology of
asthma is only partially understood, likely due to the multiple environmental and genetic
risk factors implicated in its pathogenesis and its complex symptomatic presentation2,15.
Although asthma is frequently defined by reversible airway obstruction, wheeze,
bronchial hyper-responsiveness, and/or inflammation, individual cases of asthma may
exhibit these characteristics and with varying frequency and severity2. Asthma has a large
heritable component16; yet, known genetic variations and heritable risk factors only
account for a small proportion of actual cases15. Also, identical twins are more likely to
both be asthmatic than fraternal twins, yet most identical twins with an asthmatic co-twin
are not affected by asthma, suggesting both genetic and non-genetic etiologies. Twin
studies have also shown that approximately one-third of the variation in age at onset of
asthma is due to genetic factors while the remaining two thirds are likely due to
environmental factors17. Thus further studies are necessary to reveal key etiologic
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elements in the pathogenesis of asthma, or its various phenotypes, which could then
become the targets for prevention or treatment.
Though it is well recognized that asthma has a multifaceted etiology, many of the
underlying mechanisms associated with asthma risk factors are still convoluted. Indeed,
many environmental and genetic components6,18 have been implicated as risk factors for,
or associated with, asthma. However, the only confirmed “cause” of the “underlying
asthma trait”, as opposed to triggers of asthmatic symptoms, is exposure to tobacco
smoke, prenatally, in childhood or in adulthood14. Studies of other possible “causes” have
produced conflicting evidence about their roles in the development of an underlying
asthma trait.
Potential environmental “causes” of asthma include pet ownership, living on a
farm, mold in homes, and antibiotic or paracetamol exposure in early childhood. Persons
with furry pets tend to have lower rates of asthma, though at least some of this
association appears to be driven by selective avoidance of pet-ownership by persons with
allergies19,20. Living on a farm has been observed as protective against the development
of asthma and other allergic diseases, possibly due to greater frequency and diversity of
microbial exposure leading to the development of a robust innate immune system ;
however, this is a hypothesized mechanism, the details of which remain unclear21. Mold
growth is more common in the homes of asthmatic children22, but most of these children
do not exhibit an allergic response to fungal molds, thus obscuring how this mechanism
could work10. Children that were exposed to antibiotics23 or paracetamol24 very early in
life are more likely to develop asthma, but this association may be a product of reverse
causation23. Both antibiotics and paracetamol are often administered to infants as
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treatment for wheeze and infants with recurrent wheeze may already be pre-disposed to
developing asthma later in life23,25. Thus many of the environmental exposures that are
recognized as risk factors for asthma also have many questions surrounding whether or
not they are causally related to asthma.
Aside from possible environmental contributions to asthma risk, as many as 100
genes have been implicated in asthma etiology6,18. Many of these were identified using
genome-wide association studies (GWAS), which interrogate a large number potential
genetic risk factors with no prior knowledge about their possible relationships with
asthma26. Replication of these associations has been inconsistent and largely
unsuccessful18,26,27. A likely reason for the lack of consistent replication among GWAS is
that many of these studies were conducted within different populations which had
different rates of genetic variation at identified loci6. It is also likely that poor replication
could be due to lack of penetrance, in which some genetic causes may be necessary but
not sufficient risk factors for asthma27. Similarly, a genetic risk factor may only influence
the development of asthma under the correct environmental or epigenetic conditions as in
gene-environment and gene-epigenetic interactions18,26.
1.2 Epigenetics and DNA methylation:
Epigenetic mechanisms, consisting of DNA methylation (DNA-M), histone
modifications, and microRNAs (miRNA), are processes which influence gene-expression
that are independent of variations to the genetic sequence. The majority of epidemiologic
research into epigenetic mechanisms of disease has focused on DNA-M, the covalent
addition of a methyl group to a carbon at the 5-position of a cytosine residue that is
followed by a guanine residue (CpG site) within the DNA, due its stability and
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technological advancement allowing for fairly rapid, accurate and affordable
measurements28. Many of these studies utilize the Illumina 450K HumanMethylation
array29 because of its high-accuracy, expansive interrogation, and affordability, though it
is limited by biased measurement of CpG sites within promoter regions and CpG islands,
and that despite having high-throughput scale, it still only measures < 2% of the 28
million total CpG sites in human DNA30. Thus, studies with this array may be missing
key elements of the DNA-M profile that may still be important in the diseases under
study; however, this is currently the most appropriate array for conducting epidemiologic
research of DNA-M across the genome30. As new technology becomes more affordable
and more accurate, the field may switch toward sequencing technologies that measure
methylation at more, or even all, CpG sites.
Most early studies of DNA-M considered it to function as a silencer of gene
expression, potentially through the inhibition of transcription factor (TF) binding31. Since
its discovery as a regulator of expression, investigators have uncovered multiple effects
of DNA-M on expression depending on where the methylation occurs within the gene32:
(1) direct gene-silencing via promoter methylation, (2) interacting with or blocking DNAbinding proteins, (3) repression of intragenic repetitive elements, and (4) influencing
alternative splicing via differential methylation at intron-exon boundaries. Complicating
the epigenetic landscape are the interactions between epigenetic mechanisms, and the
interactions between genetic and epigenetic variation. For instance, methylation at
particular sites can lead to histone modifications and vice versa33. Also, although
epigenetic modifications do not alter the genomic sequence, they can be influenced by
genetic variation and can be induced by environmental stimuli18 making for complex
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multi-factor interactions. These interactions between genetic variation and levels of DNA
methylation are referred to as methylation quantitative trait loci (methQTLs)34–36. Despite
these complex interacting mechanisms, DNA-M has been shown to have independently
important role in the regulation of gene expression and thus likely plays a role in many
complex diseases.
Role for Epigenetics in Asthma Etiology, a brief review:
Epigenetic mechanisms are known to play major roles in cellular differentiation
and immune cell activation33. DNA methylation biomarkers have been implicated in
airway inflammation37, immune cell fate, and asthma33. The majority of epidemiologic
research in this area has focused on candidate regions of the genome known to be
important in asthma pathogenesis, such as genes driving CD4+T cells toward Th2 rather
than Th1 phenotypes, an important polarization that occurs in asthmatics8. Such research
has shown that the loss of DNA-M, accompanied by histone modifications at Th2
cytokine loci (IL4, IL5, and IL13), promote a Th2 response whereas the presence of
DNA-M within the IL4 locus has been shown to promote a Th1 response38. Statistical
interactions between genetic variants and DNA-M within the genes for the IL4-receptor
(IL4R) and GATA Binding Protein 3 (GATA3), are also involved in Th2 polarization,
contribute to asthma risk in a potentially age-dependent pattern35,39. The majority of
strong associations between DNA-M and asthma have been observed within these and
other genes involved in T-cell differentiation40, though investigators have also found
associations related to specific characteristics of asthma such as FeNO and
bronchodilator responsiveness. Higher levels of FeNO were associated with lower levels
of DNA-M the arginase genes (ARG1 and ARG2)41, IL6, and iNOS37 implicating that
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DNA-M plays an important role in the production of nitric oxide, which is an important
marker of airway inflammation and eosinophilic asthma. Others have shown that higher
levels of DNA-M within the promoter of the adrenoceptor β2, Surface (ADRB2), which
can induce relaxation of smooth muscle in the airways, have been associated with
decreased severity of dyspnoea and trended towards improved spirometry measures42.
Taken together, these findings indicate that DNA-M plays many roles in regulating
different biological pathways that are important in asthma etiology.
1.3 Objectives:
Purpose of the dissertation:
The overarching goal of this dissertation was to identify novel genetic and
epigenetic loci associated with asthma and complex wheeze phenotypes, and explore
whether a novel set of genes associated with young adult wheeze could also be predictive
of infant wheeze. We attempted to do this by conducting a genome-wide DNA-M study
of physician-diagnosed asthma, a cross-sectional study of Th2-path genetic and
epigenetic variations among complex wheeze phenotypes, and a prospective study of the
expression and DNA-M of a novel gene-set and infant wheeze.
Specific Aims:
1. Aim 1: To identify CpG loci associated with prevalent asthma at age 18 from a
genome-wide DNA methylation dataset with a two-stage design.
Research Question 1.1: What parameters in the recursive Random Forest (RF)
algorithm need to be changed from their default values?
Research Question 1.2: Stage 1 – What epigenetic loci are selected via
recursive RF feature selection?
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Research Question 1.3: Stage 1 – Was the site selection from recursive RF
feature selection confounded by cell-type proportions?
Research Question 1.4: Stage 2 – Which sites selected from Stage 1 can be
corroborated with multivariable logistic regression for their associations with
asthma status?
Research Question 1.5: Stage 2 – Are these sites associated with markers of
lung dysfunction or allergic inflammation of the lung?
Research Question 1.6: What are the biological functions of the genes that the
selected CpG sites are in?
2. AIM 2: To explore whether the combined genetic and epigenetic variation within an
asthma-associated pathway (ie. the Th2 path) can improve our classification of
asthmatic phenotypes at age 18.
Research Question 2.1: Are specific genetic and epigenetic variations in the
selected path able to classify different asthma phenotypes?
3. AIM 3: To identify whether the gene-set associated with our top DNA-M findings
from Aim 1 are differentially expressed in cord blood in relation to infant wheeze.
Research Question 3.1: How are gene expression levels related within the
selected gene-set?
Research Question 3.2: Which genes within the gene-set are differentially
expressed in cord blood samples in relation to wheeze within the one year of
birth?
Research Question 3.3: Which genes within the selected gene-set are
correlated

(positively

or

negatively)
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with

DNA-M

levels?

CHAPTER 2
GENOME-WIDE DNA METHYLATION ASSOCIATION STUDY OF ASTHMA
2.1 Introduction:
Asthma is a common chronic respiratory disease affecting around 334 million
people worldwide13, causing substantial health care costs and morbidity-related
absenteeism14. Over the previous two decades, many studies have sought to characterize
the underlying mechanisms leading to the development and persistence of asthma. Yet,
the etiology of asthma remains only partially understood, likely due to its complex
physiology and the multiple environmental and genetic risk factors implicated in its
pathogenesis2,14.
Asthma is defined by multiple symptoms and characteristics such as airflow
obstruction, bronchial hyper-responsiveness and airway inflammation. However,
individual cases of asthma may exhibit only some of these characteristics and with
varying frequencies and severities. This dynamic leads some to hypothesize that asthma
is a diagnosis that encompasses multiple diseases, each of which may have its own
unique etiology and pathophysiology2,38. Also, asthma has a substantial heritable
component14,16, known genetic variations and heritable risk factors only account for a
small proportion of actual cases15.
Previous evidence suggests that asthma has no individual cause27; indeed, many
environmental risk factors and as many as 100 genes18 have been implicated in studies of
asthma. Epigenetic mechanisms, which control heritable variations in gene-
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expression not related to changes in genomic sequence32, have received recent attention
in studies of asthma because these mechanisms are considered to be heritable and can be
altered via environmental exposures, particularly exposures that occur in utero14,38,43. One
of the most thoroughly studied epigenetic mechanisms is DNA methylation (DNA-M),
which is the covalent addition of a methyl group to the DNA at a cytosine residue that is
followed guanine (CpG site); this acts as an important regulator of gene transcription and
may influence alternative splicing32.
Recent work has shown that epigenetic mechanisms are important in regulating
the expression of pro- and anti-inflammatory cytokines, which drive T-cell differentiation
as well as the severity and duration of an inflammatory response44. Also a number of
association studies have found variations in DNA-M associated with asthma status40, lung
function45, and nitric oxide synthesis41. These studies have provided strong evidence that
epigenetic mechanisms play key roles in the biological processes that result in asthmatic
predisposition and the onset of symptoms. Thus further studies are necessary to reveal
key epigenetic elements in the pathogenesis and persistence of asthma, or its various
phenotypes, which can then become the targets for prevention or treatment.
We conducted an exploratory study aimed at identifying novel DNA-M markers,
from a genome-wide screening, which could be effective classifiers of current prevalent
asthma and which may reveal some of the underlying role that DNA-M plays in the
pathogenesis or persistence of asthma. Because asthma is heterogeneous condition, we
were also interested in learning whether some these markers were more strongly
associated with asthma among those with and without allergic sensitization, and for
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specific phenotypic characteristics of asthma such as airway obstruction (FEV1/FVC
Ratio), bronchodilator reversibility (BDR) and fraction of exhaled nitric oxide (FeNO).
2.2 Methods:
The Isle of Wight birth cohort
The Isle of Wight (IOW) birth cohort was established to study the natural history
of asthma and allergies in children born between January 1, 1989 and February 28, 1990
in Isle of Wight, UK. The study was approved by the local research ethics committee
(now named the National Research Ethics Service, NRES Committee South Central –
Southampton B, 06/Q1701/34) and written informed consent was provided by the infants’
parents. Details about the birth cohort have been described in detail elsewhere46,47. After
exclusion of adoptions, prenatal deaths and refusals, 1,456 children were enrolled, and
followed-up at 1 (n=1,167; 80.2%), 2 (n=1,174; 80.6%), 4 (n=1,218; 83.7%), 10
(n=1,373; 94.3%), and 18 (n=1,313; 90.2%) years of age. At each follow-up, participants
were administered detailed questionnaires and evaluated for manifestations of allergic
disease. Questionnaires included the International Study of Asthma and Allergies in
Childhood (ISAAC)5 as well as study-specific questions about allergic disease and
relevant risk factors. At the 18 year follow-up, questionnaire data was obtained via inperson interview (n=864; 66%), by telephone (n=421; 32%), or by mail (n=28; 2%).
Most of those who attended the follow-up visit in-person were also assessed via
spirometry, BDR, FeNO, and skin prick tests (SPTs). At this 18-year follow-up a random
subset of female (n=245) and male (n=125) participants were selected to take part in
epigenetic screening.
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Dependent Variables
The primary dependent variable for this study was dichotomous prevalent asthma
status (asthma vs. no asthma), determined by questionnaire. Participants were determined
to have asthma if they had an affirmative answer to “Have you ever had asthma?”, as
well as an affirmative response to either “Have you had wheezing in the last 12 months?”
or “Have you had asthma treatment in the last 12 months?”
Continuous measures of lung volume and airway obstruction were assessed via
spirometry at age 10 and 18 years. Lung function measurements were performed using a
Koko Spirometer and software with a desktop portable device (PDS Instrumentation,
Louisville, USA), according to American Thoracic Society guidelines

48,49

. Prior to lung

function measurements children were required to be free from respiratory infection for 14
days and to not be taking oral steroids. In addition, they were required to abstain from
any beta-agonist medication for 6 hours and from caffeine intake for at least 4 hours.
Forced expiratory volume in one second (FEV1) measured the volume of air (in liters)
exhaled over the first second of a forced expiration done with maximal effort. Forced
vital capacity (FVC) was the total volume of air that could be expired after full
inspiration. The FEV1/FVC ratio was calculated by dividing FEV1 by FVC, and
represents the proportion of the vital capacity that an individual can expire over one
second, given maximal effort. BDR measured the percent change in FEV1, taken before
and after administration of 600 ng/ml salbutamol, which is a bronchodilator. Percent
change for BDR was calculated via pre-bronchodilator FEV1 minus post-bronchodilator
FEV1 divided by the pre-bronchodilator FEV1 multiplied by 100.
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Fraction of exhaled nitric oxide (FeNO) is a marker of airway inflammation.
FeNO measurements (Niox mino, Aerocrine AB, Solna, Sweden) were obtained prior to
spirometric assessments and in accordance with American Thoracic Society (ATS)
guidelines. Expiratory flow against resistance was maintained at 50 ml/s to avoid
contamination of the airways. Participants with a current infection, as well as those with
asthmatic symptoms or treatment (with antibiotics or oral steroids) within the previous
two weeks, were rescheduled for a later date. Because the distribution of FeNO was
heavily positively skewed, all parametric analyses were performed with log-transformed
FeNO, which better approximated a normal distribution.
Atopy status, was assessed by skin prick tests (SPT) administered via a standard
method50 with a battery of 11 allergens. Food allergens tested were cows’ milk, hens’
egg, peanut and cod. Inhalant allergens tested were house dust mite, cat, dog, Alternaria
alternata, Cladosporium herbarium, grass pollen mix, and tree pollen mix. Histamine
and saline acted as positive and negative controls, respectively (Alk-Abello, Horsholm,
Denmark). Positive SPTs were defined as having a mean wheal diameter of 3 mm greater
than the negative control; if the positive control yielded a diameter less than 3mm, the
test was deemed inconclusive. Participants with at least one positive SPT were defined as
atopic, while those with no positive SPTs were defined as not having atopy.
Data Collection and DNA Methylation
Blood samples for epigenetic screening were collected at the 18 year follow-up,
DNA was extracted from whole blood using a standard salting out procedure

51

. DNA

concentration was determined by the PicoGreen dsDNA quantitation kit (Molecular
Probes, Inc., OR, USA). One microgram of DNA was bisulfite-treated for cytosine to
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thymine conversion using the EZ 96-DNA methylation kit (Zymo Research, CA, USA),
following the manufacturer's standard protocol. Genome-wide DNA methylation was
assessed using the Illumina Infinium HumanMethylation450K BeadChip (Illumina, Inc.,
CA, USA), which interrogates >484,000 CpG sites, regions of DNA where a cytosine
nucleotides are followed by a guanine nucleotide, associated with approximately 24,000
genes. The BeadChips were scanned using a BeadStation, and the methylation levels (
value, described below) were calculated for each queried CpG locus using the
Methylation Module of BeadStudio software. Arrays were processed using a standard
protocol as described elsewhere52, with multiple identical control samples assigned to
each bisulphite conversion batch to assess assay variability and samples were randomly
distributed on microarrays to control against batch effects.
Data Cleaning
The program for data cleaning was written in R (R Development Core Team,
2012). Quality control (QC) measures were employed to improve the reliability of data
prior to analysis. In our study, the detection P-value reported by BeadStudio (Illumina
software to process raw intensities) was used as a QC measure of probe performance.
Probes whose detection P-values > 0.01 in >10% of the samples were removed53. The
methylation data were then preprocessed and technical variations removed via peakcorrection using the Bioconductor IMA (Illumina methylation analyser) package54.
Dropping control probes and probes with poor detection P-values yielded 383,998
remaining probes; since males and females were studied together, CpGs on sex-specific
(X and Y) chromosomes were dropped. The arrays were processed in three different
batches; batch number was recorded as a categorical variable which was used in ComBat
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to adjust for inter-array variation55. A very conservative approach was utilized for
addressing systematically biased probes. We also excluded all probes with SNPs that had
a minor allele frequency (MAF) > 1.0% in European populations (or any population if
European-specific MAF was not available) and within 10 nucleotides of, or directly at,
single base extension via dbSNP13756, resulting in a final set of 248,336 CpGs for
analysis. Dropping this large set of potentially biased probes was necessary because the
variable selection method depends on a conditional variable importance metric, which
means that the selection of biased probes could adversely affect the selection of otherunbiased probes.
Methylation levels for each queried CpG were calculated as beta () values.
These represent the proportions of methylated probes for each specific CpG site and can
be interpreted as percent methylation. The β values close to 0 or 1 tend to suffer from
severe heteroscedasticity57. The β values were utilized for RF, described below, which is
a non-parametric method and does not assume a normal distribution. However, for
parametric statistical analyses, we utilized M-values which address the issue of
heteroscedasticity and were calculated via log2(β / (1-β))57. Because M-values expand the
distribution of the methylation levels, they may emphasize outliers; thus when using Mvalues, strong outliers were recoded as missing. Potential outliers were identified using
adjusted boxplots and a coefficient of 2.5 via the robustbase package in R.
Random Sampling: Stage-1 vs Stage-2
The epigenetic sample was randomly divided into two independent sub-samples.
To create the stage-1 sample, 25% of participants with asthma and 25% of participants
without asthma were randomly selected from the epigenetic sample (N=370), yielding a
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discovery data set (nS1=91). The stage-2 validation data set (nS2=279) included all
samples not selected into the discovery data set. To improve the likelihood that findings
selected from stage-1 could be validated in stage-2, we compared the prevalence of
asthma and gender, as well as the mean values for airway obstruction and inflammation
across the two sub-samples. Differences in prevalence of asthma or gender, between the
stage-1 and stage-2 samples, were assessed with Pearson’s Chi-squared tests. Students Ttests were used to determine whether the mean values of continuous variables differed
between the stage-1 and stage-2 samples. The specific analyses utilized within each stage
are detailed below.
Stage 1 (nS1=91) – Recursive RF feature Selection
For stage-1 we conducted recursive RF feature selection 58,59 described below. RF
is a non-parametric machine learning technique that can deal with substantially large
numbers of predictors (p) relative to the number of samples (n), it is robust to outliers and
noise, and it naturally incorporates conditional effects into the model via recursive binary
partitioning without needing to specify interactions a priori

60

. The RF algorithm has

been thoroughly described elsewhere60,61. Briefly, this algorithm produces a series of
classification trees, grown from bootstrapped training samples with replacement; each
participant’s outcome status is predicted from the aggregate of all trees in which they
were not part of the training sample. We used ‘balanced sampling’, by specifying by the
sampsize parameter, to draw the same number of observations from the minority class
and majority class for each bootstrap sample, so that each individual classification tree
was grown from a balanced sub-sample58. We also altered the parameters for the number
of predictors to test per node (mtry = 10% of all predictors available) and the number of
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trees to grow in the forest (ntree = 7500) due to sparsity in the data and to produce stable
VIMs, respectively.
We effectively implemented the RF algorithm recursively as a means of reducing
the size of the data62. For the recursive RF feature selection we (1) ran the RF algorithm
on all available predictors via the randomForest package in R63, (2) extracted out-of-bag
(OOB) misclassification rates and the variable importance measures, (3) sorted the
predictors by their variable importance measures (VIMs), (4) excluded half of the
predictors with the smallest VIMs, and (5) repeated the sequence until the stop criteria
was met. Our stop criterion was a leveling-off of the asthma-specific misclassification
rate; this would indicate that the predictors contributing noise to the RF classifications
had been effectively excluded and the remaining predictors offered some ability to
distinguish between asthmatics and non-asthmatics. Predictors that remained once the
stop criteria were met were then annotated with relevant genetic information and
analyzed for significant associations with asthma in the stage-2 validation sample.
Stage 2 (nS2=279) – Validation Tests in Independent Sample
The methylation levels for the selected CpGs were then converted to M-values as
previously described, then tested for crude association with asthma status via logistic
regression. The p-value distribution was then investigated via histogram, to determine
whether small p-values from the validation tests were likely due to random chance. We
generated q-values to estimate the false discovery rate (FDR)64 using the qvalue package
in R65. Sites from the stage-2 analyses that were within a 10% FDR were then selected as
our positive findings. We then validated that the direction (positive vs. negative) of the
association, between methylation levels and asthma, was the same by plotting the
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parameter estimates for the selected sites for both stage-1 and stage-2 logistic regression
models. Any sites that did not show the same direction of association were excluded from
our positive findings.
Stage 3 (N=370) – Characterization of Findings
Post-hoc analyses were then conducted on the positive findings from stage-2
analyses, in the full sample. We assessed whether the odds of higher average methylation
was greater among asthmatics compared to non-asthmatics using logistic regression.
Potential confounders (sex and cell-type proportions from blood samples) were
determined a priori. Due to logistical constraints, complete blood counts (CBC) were not
possible for our participants, thus we predicted cell type proportions of CD8T cells,
CD4T cells, natural killer cells, B-cells, monocytes, eosinophils and other granulocytes66
using constrained projection67,68 via the minfi package in R69. To determine whether the
observed associations with asthma were driven by any confounding factors, we produced
three logistic regression models for each CpG site with asthma status as the dependent
variable and M-values as the independent variable, while including: (1) no additional
covariates for Model 1, (2) confounders associated with asthma status via t-tests as
adjustment covariates for Model 2, and (3) all potential confounders identified a priori as
adjustment covariates for Model 3. CpG sites that retained independent associations with
asthma, after adjustment for confounders, were considered as our top findings.
As a post-hoc analysis, we investigated whether our top findings between DNAM and asthma were also associated with some continuous measures of airway
obstruction, reversible airway obstruction, and airway hyper-reactivity commonly used in
the evaluation and management of asthma: FEV1/FVC, BDR, and FeNO, respectively. To
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conduct these analyses, we implemented Model 1 (crude) and Model 3 (adjusted) linear
regression models for each of the above dependent variables. Also, because the
underlying biological mechanisms leading to airway obstruction may differ between
those with allergic- versus non-allergic-asthma, we conducted a sensitivity analysis to see
whether the observed associations differed between those with and without atopy. For
these analyses we conducted Model 1 (crude) and Model 3 (adjusted) regressions
(logistic for asthma status, and linear for FEV1/FVC, BDR, and FeNO), stratified by
atopy status. Normal values of FEV1, FVC are dependent on age, sex, and height, thus all
statistical analyses utilizing these, or combinations of these, measures included sex and
height as adjustment covariates (all participants were matched on age by study design).
Last, to understand the functionality of the selected CpG sites, pathway analysis
was performed on the genes annotated to CpG sites that were internally validated in
stage-2. Where a CpG site was annotated to more than one gene, all annotated genes were
included in the list. Three CpGs were not annotated to any gene, so were not included in
pathway analysis. The resulting list of 22 asthma-associated genes and their parameter
estimate values was submitted to Ingenuity Pathway Analysis software (IPA, Qiagen),
using default analysis parameters. The networks tool was used to find gene expression
networks containing multiple differentially methylated genes.
2.3 Results:
All participants were 18 years old at the time of epigenetic screening for DNA-M
and ascertainment of physician diagnosed asthma status. Within our sample, 13.9%
(n=51) of participants were asthmatic, meaning they had received an asthma diagnosis
from a physician at any point in their life and had asthmatic symptoms and/or took an
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asthma medication within the previous 12 months. The majority of our sample was
female (66.2%), and there was no difference in the proportion of males and females
between asthmatics and non-asthmatics. Asthmatics had substantially higher prevalence
of concurrent atopy, determined by SPTs, (66.0% vs 29.5%; χ2 P-value < 0.0001) (Table
2.1). We also compared a number of lung function measures, markers of airway
reactivity, and proportions of circulating cell-types, between asthmatics and nonasthmatics. On average, there was no difference in FVC (means: 4.50 vs 4.48; T-test Pvalue = 0.93), but asthmatics had lower FEV1 (means: 3.74 vs 3.94; T-test P-value =
0.079), lower FEV1/FVC Ratio (means: 0.83 vs. 0.88; T-test P-value = 0.0006) greater
BDR (means: 7.74 vs. 4.17; T-test P-value = 0.0004) and greater FeNO (medians: 21.0 vs
14.0; T-test P-value = 0.0005).
Because methylation measurements were obtained from peripheral blood samples,
and persons with asthma likely have different circulating blood compositions than those
without asthma, we also compared the proportions of cell types between asthmatics and
non-asthmatics as estimated using the Houseman method

67,68

. On average, those with

asthma had significantly greater proportions of circulating B-Cells (0.053 vs 0.045; T-test
P-value = 0.028) and eosinophils (0.043 vs 0.021; T-test P-value = 0.0007) when
compared to those with asthma, but only minor differences for all other cell-types.
To conduct the genome-scale DNA-M screening, this study first implemented a
supervised feature selection on DNA-M sites from the Illumina 450K microarray (stage1), then validated associations between DNA-M and asthma status for the set of selected
features (stage-2), and lastly tested the validated sites for their associations with asthma,
and with measures of airway-obstruction and hyper-reactivity, while adjusting for cellular
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heterogeneity and sex (stage-3). To implement this design, the full data set (N=370) was
randomly divided into two independent sets: a stage-1 sample (nS1=91) used for feature
selection and a stage-2 sample used for validation testing (nS2=279). Prior to running the
stage-1 analyses, we compared the stage-1 and stage-2 samples to ensure that
randomization was effective for important variables: prevalence of asthma, prevalence of
female sex, average values for airway obstruction and airway hyper-reactivity, as well as
average cell-type proportions (Table 2.2). Only BDR was significantly different between
stage-1 and stage-2 samples (4.99 vs. 3.58; T-test P-value = 0.006).
Stage 1 Results (nS1=91) – Recursive RF feature Selection
The RF feature selection was implemented on the stage-1 sample, with a starting
set of 248,336 CpG sites. This was a four step process which utilized RF to sort the
predictors by their VIMs, then dropped least informative predictors in recursive
iterations; each iteration reduced the set of predictors by 50%, until all uninformative
predictors had been excluded. The overall forest’s ability to predict asthma in the
discovery sample was tracked across all iterations. We observed a leveling-off of the
misclassification rates at the 12th iteration, corresponding to zero misclassification of
asthmatics and 1% misclassification of non-asthmatics in the stage-1 sample (Figure 2.1).
This iteration included 121 CpG sites as possible predictors, which were annotated with
relevant genetic information and included in the supplemental materials. The forest
grown in the 12th iteration of stage-1 was then used to predict asthma status of stage-2
participants, with very poor accuracy (Sensitivity=20.5% & Specificity=92.9%).
The low sensitivity was likely due to the recursive RF data reduction over-fitting
to the stage-1 sample, resulting in the inclusion of sites that were spuriously associated
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with asthma and over-fitting the cut-points of truly associated sites used to distinguish
asthmatics from non-asthmatics in the stage-1 sample. To determine which of the
selected sites were likely to be truly informative for asthma, the selected sites were then
tested for their crude associations with asthma status via logistic regression in the stage-2
sample.
Stage 2 Results (nS2=279) – Validation Tests in Independent Sample
The p-values for the crude associations exhibited a strong left peak with positive
skew (Figure 2.2), indicating that the small p-values were unlikely to be purely chance
findings. Thus q-values were generated for the 121 crude tests, 24 of which were
associated with asthma (P-value range: 0.000045 – 0.027) at a FDR of 10% (Table 2.3).
For all of these 24 sites, the direction of the association was the same for stage-1 and
stage-2 logistic regression models (Figure 2.3). The majority of these sites were
negatively associated with probability of asthma: for 21 (87.5%) of the validated sites,
asthmatics were more likely to have lower average methylation levels than nonasthmatics; asthma was associated with higher average methylation for only 3 validated
sites (12.5%). Given that these 24 sites were selected from stage-1 and validated in stage2, for both direction of association and statistically significant FDR q-values, they were
selected as candidate CpGs for follow-up analyses to better understand their associations
and potential roles in asthma.
Stage 3 (N=370) – Characterization of Findings
The remaining analyses utilized methylation data from all participants (N=370),
to provide the most accurate estimates of the relationships between DNA-methylation at
these candidate CpGs and asthma (Table 2.4). We first produced crude logistic regression

24

models (Model 1) for each of the 24 sites with asthma status as the dependent variable
and M-values as the independent variable. As expected, all sites had strong crude
associations with asthma (negative OR range: 0.09 to 0.34; positive OR range: 7.99 to
9.51) and 95% CIs that excluded the null for all.
Then we added the proportions of eosinophils and B-cells, which were present in
greater proportions among asthmatics (T-test P-values = 0.0007 and 0.0396,
respectively), as covariates to the regression models (Model 2) for each site. We found
that the majority of the ORs attenuated towards the null and 14 (58.3%) of the confidence
intervals crossed the null, indicating that these sites were not independently associated
with asthma, and may instead represent markers of eosinophils or B-cells. However, 10
sites retained independent associations with asthma after adjustment (negative OR range:
0.13 to 0.35; positive OR range: 8.96 to 10.56).
Last, we added in overall cellular heterogeneity (proportions of CD8T cells,
CD4T cells, B-cells, monocytes, natural killer cells, eosinophils, and other granulocytes)
and sex as covariates (Model 3). After adjusting for sex and proportions of all predicted
cell-types, only one more site lost statistical significance: 15 (62.5%) of the 95%
confidence intervals crossed the null. Given the potential dependence of associations
between DNA-M and asthma on overall cellular heterogeneity67,70 and sex71, as well as
the consistency of our results between Model 2 and Model 3, we considered the 9 sites
that retained independent associations with asthma in Model 3 as our top positive
findings. Lower average methylation levels were independently associated with increased
probability of asthma at cg25578728 in CHD7 (Model 3 OR = 0.109 (0.034, 0.333)),
cg16658191 in HK1 (Model 3 OR = 0.129 (0.032, 0.481)), cg00100703 in UNC45B
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(Model 3 OR = 0.177 (0.059,0.502)), cg07948085 [intergenic] (Model 3 OR = 0.280
(0.095, 0.784)), cg04359558 in LITAF (Model 3 OR = 0.352 (0.172, 0.694)), and
cg20417424 in ST6GALNAC5 (Model 3 OR = 0.353 (0.118, 0.998)). Whereas higher
average methylation levels were independently associated with increased probability of
asthma at cg19974715 [intergenic] (Model 3 OR = 8.785 (2.536, 31.879)), cg01046943
in NUP210 (Model 3 OR = 9.626 (2.229, 43.439)) and cg14727512 in DGCR14 (Model
3 OR = 10.464 (3.021, 38.637)). One site, cg19232164 in REXO2, retained independent
associations with asthma in Model 2 (OR = 0.254 (0.065,0.936)) but not in Model 3 (OR
= 0.281 (0.073, 1.073)).
To investigate which cell-types were the strongest confounders of our observed
associations we generated two correlation matrices of: (1) pair-wise correlations of
predicted cell proportions and the 9 sites with independent associations for Matrix 1
(Figure 2.4), as well as (2) pair-wise correlations of predicted cell proportions and the 15
sites that were confounded by cellular heterogeneity for Matrix 2 (Figure 2.5).
Interestingly, although all 9 sites in Matrix 1 showed strong associations with asthma
independent of cellular heterogeneity, methylation levels at some of these sites were still
moderately or even strongly correlated with proportions of eosinophils. For instance,
cg16658191 was moderate-to-strongly correlated with proportions of eosinophils (r= 0.67) while cg07948085 (r= -0.54), cg20417424 (r= -0.46), and cg00100703 (r= -0.44)
were moderately correlated with proportions of eosinophils. All other sites in Matrix 1
only exhibited weak correlations (|r| < 0.40) with any cell proportions. Although
proportions of B-cells differed between those with and without asthma, methylation
levels at the 15 CpGs in Matrix 2 only exhibited very weak correlations with B-cell
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proportions but all were strongly negatively correlated with eosinophil proportions. CpG
sites in Matrix 2 exhibited very weak correlations with any of the other cell-type
proportions, indicating that eosinophils were likely driving the majority of confounding
from cellular heterogeneity.
Because the underlying biological mechanisms leading to asthmatic symptoms
may differ between those who have allergic hypersensitivity and those who do not, we
conducted a sensitivity analysis to determine whether the associations between DNA-M
and asthma differed between those with and without atopy among our top 9 findings.
Persons with atopy were far more likely to be asthmatic than persons without atopy
(26.2% vs. 7.1%). Also circulating cell-mixture showed larger differences between
persons with and without asthma, among those with atopy: asthmatics had lower
estimated proportions of natural killer cells (0.06 vs 0.08; T-test P-value = 0.0096) and
higher estimated proportions of both B-cells (0.06 vs 0.05; T-test P-value = 0.0211) and
eosinophils (0.05 vs 0.03; T-test P-value = 0.0027). However, among those without
atopy, there were no significant differences for any estimated cell-type proportions
between those with and without asthma. We also compared whether measures of airway
obstruction (FEV1/FVC Ratio), reversible airway obstruction (BDR), and airway hyperreactivity (FeNO) were differed between those with and without atopy. As expected,
higher log-FeNO was associated with asthma, but only among those with atopy (T-test Pvalue = 0.006), whereas FEV1/FVC ratio and BDR were associated with asthma among
participants with (T-test P-values: 0.0153 and 0.0045, respectively) and without (T-test
P-values: 0.0094 and 0.043, respectively) atopy.
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Crude logistic regression models, stratified by atopy status (Table 2.5), revealed
that all sites were strongly associated with asthma among persons with atopy, except for
cg01046943 in NUP210; while 6 of the 9 sites were associated with asthma among those
without atopy. After adjusting for sex and cellular heterogeneity cg16658191 in HK1
(ORAtopy = 0.09 (0.01,0.77)), cg04359558 in LITAF (ORAtopy = 0.29 (0.10,0.81)), and
cg14727512 in DGCR14 (ORAtopy = 22.99 (3.43,194.38)) were only associated with
asthma among persons with atopy; cg00100703 in UNC45B (ORNo-Atopy = 0.03
(0.01,0.19)), cg07948085 [intergenic] (ORNo-Atopy = 0.15 (0.02,0.89)), and cg01046943 in
NUP210 (ORNo-Atopy = 35.26 (3.32,444,37)) were only associated with asthma among
persons without atopy; both cg25578728 in CHD7 (ORAtopy = 0.15 (0.02,0.82); and ORNoAtopy

= 0.06 (0.01,0.35)) and cg19974715 [intergenic] (ORAtopy = 26.32 (3.57,251.98); and

ORNo-Atopy = 8.32 (1.22,59.89)) were associated with asthma, irrespective of atopy status.
Finally, cg20417424 in ST6GALNAC5 was not associated with asthma within either
atopy-strata after adjustment for sex and cellular heterogeneity, though the CI only barely
crossed the null among those with atopy (ORAtopy = 0.20 (0.03,1.06)). These findings
provide evidence that there may be some shared epigenetic regulation (or dys-regulation)
involved in asthmatic processes, but also that there are likely some epigenetic alterations
that are unique to allergic and non-allergic asthma, respectively.
We next investigated whether the top 9 sites were associated with various
measures of overall airway obstruction (FEV1/FVC ratio), reversible airway obstruction
(BDR), and airway hyper-reactivity (FeNO), stratified by atopy status (Table 2.6).
Because the established normal values for FEV1 and FVC are dependent on age, height
and sex, we included height and sex in all statistical models for FEV1/FVC ratio and

28

BDR. Higher average methylation levels at cg00100703 in UNC45B were associated with
increased FEV1/FVC ratio (beta = 0.03 P-Value = 0.032), among those without atopy,
and with decreased average log-FeNO (beta = -0.21 P-Value = 0.024) among those with
atopy. Higher average methylation levels at cg07948085 [intergenic] were associated
with lower FeNO (beta = -0.20 P-Value =0.028), but only among those with atopy. Also,
higher methylation levels at cg14727512 in DGCR14 were associated with higher logFeNO (beta = 0.32 P-Value = 0.005) among those with atopy. Higher methylation levels
at cg16658191 in HK1 were associated with lower BDR (beta = -4.91 P-Value = 0.036),
but only among those with atopy. Higher methylation levels at cg19974715 [intergenic]
were associated with increased BDR (beta = 4.89 P-Value = 0.016), only among those
with atopy. Lastly, higher methylation levels at cg20417424 in ST6GALNAC5 were
associated with increased FEV1/FVC ratio , both for those with (beta = 0.05 P-Value =
0.022) and without (beta = 0.03 P-Value = 0.022) atopy as well as decreased BDR (beta =
-2.41 P-Value = 0.017) only among those without atopy.
The functional analyses for the 22 genes submitted to IPA revealed five
statistically significant canonical pathways related to trehalose degradation II (P-value =
3.41E-03), GDP-glucose biosynthesis (P-value = 6.80E-03), glucose and glucose-1phosphate

degradation

(P-value

=

7.93E-03),

UDP-N-acetyl-D-galactosamine

biosynthesis II (P-value = 1.02E-02), and CDP-diacylglycerol biosynthesis I (P-value =
1.80E-02). Interestingly, the top network associated with our gene list, Cell Morphology,
Tissue Morphology, Cellular Development, (Figure 2.6) included 7 of the 22 genes from
our list: HK1, LITAF, ALCAM, KCNH2, SIK2, ST6GALNAC5, and DGCR14.
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2.4 Discussion:
Asthma was prevalent in 13.8% of our epigenetic sub-sample; the majority of
which had atopy (66%) and on average had normal FEV1/FVC (mean = 83%), though
lower than non-asthmatics, high BDR (mean = 7.74 L), and high FeNO (median = 21.00
log(ppb)). Using a unique feature-selection technique and two-stage design, we identified
24 CpG sites within a 10% FDR associated with asthma-status at age 18; nine of which
had associations with asthma, atopy-specific asthma, airway obstruction, reversible
airway obstruction, and/or airway hyper-reactivity, independent of cellular heterogeneity
and sex. Gene annotations for these nine sites (Table 2.7) revealed that all of our top
findings were novel, as none of the genes encompassing these CpG sites had been
previously implicated in studies of asthma; though many of them are involved in
biological processes that may be important in asthma pathogenesis and persistence. Many
of the top sites were within genes involved in a network that influences cell and tissue
morphology. The present findings require replication in other cohorts with larger
samples.
Three of these CpG sites were most strongly associated with asthma among
persons with atopy: cg16658191 within the body (or 1st exon) of hexokinase 1 (HK1),
cg14727512 within the 3’UTR of DiGeorge Syndrome Critical Region Gene 14
(DGCR14) and within the 1st exon of testis-specific serine kinase 2 (TSSK2), and
cg04359558 within the body of lipopolysaccharide-induced TNF-α factor (LITAF).
Among persons with atopy, methylation levels at cg16658191 were also associated with
BDR, a measure of reversible airway obstruction, and methylation levels at cg1427512
were associated with FeNO, a marker of airway inflammation. HK1 encodes for a

30

hexokinase-1 which is integral in glucose metabolism, provides resistance to TNFinduced apoptotic signals72, and mutations within this gene have been associated with
hemolytic anemia in mice73. Eosinophils of asthmatics not on corticosteroids74 and
activated T-cells of atopic asthmatics75 have been shown to be resistant to apoptotic
signals resulting in prolonged pro-inflammatory activity, though many aspects of the
molecular mechanisms involved in this resistance are still unclear75. DGCR14 is thought
to encode for a component of a spliceosome. Deletions at or near this gene have been
implicated in the etiology of DiGeorge syndrome, a heterogenous developmental disorder
that often is characterized by T-cell deficiency and/or craniofacial malformations76. Also
of note, increased expression of DGCR14 has been shown to up-regulate IL17α, thus
promoting Th17 cell differentiation77, and Th17 cells have been implicated for their roles
in non-atopic and steroid-resistant asthma78. LITAF, which has primarily been studied in
mouse models, encodes for a protein that is expressed in response to lipopolysaccharide
(LPS) challenge, and forms a complex with STAT6B which then up-regulates the
transcription of monocyte chemoattractant protein-1 (MCP-1)79 and tumor necrosis factor
alpha (TNF-alpha)80. Both MCP-1 and TNF-alpha are pro-inflammatory cytokines, and
thus over-expression could lead to prolonged inflammatory states79,80.
Another three sites were most strongly associated with asthma among those
without atopy: cg07948085 [intergenic], cg01046943 within the body of nucleoporin
210kDa (NUP210), and cg00100703 within the 3’UTR of unc-45 homolog B (UNC45B).
Interestingly, despite these sites being most strongly associated with asthma among
persons without atopy, cg07948085 and cg00100703 were associated with FeNO among
persons with atopy; whereas cg00100703 was associated with FEV1/FVC ratio among
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persons without atopy. NUP210 encodes for a major component of the nuclear pore
complex which is essential for transporting molecules between the nucleus and the
cytoplasm; this particular component is involved in muscle cell differentiation and is
integral for maintaining nuclear envelope/ER homeostasis81. NUP21 was also found to be
up-regulated in multiple tumor cell lines82 and may have some anti-apoptotic effects81.
The functions of the protein encoded by UNC45B are largely unknown, although it is
thought to have a role in myoblast fusion and sarcomere organization83. However,
UNC45B does lie within chromosomal region 17q12, which is within the asthma
susceptibility region 17q12-2171,84–86. SNPs within 17q12-21 the genes ZPBP2,
ORMDL3, GSDMA, and GSDMB have previously been associated with childhood asthma
and with FeNO levels85,87. Berlivet et al (2012) recently found that promoter methylation
within these genes was highly correlated with their expression levels, providing evidence
for epigenetic-genetic interactions that may alter asthma risk87.
One site, cg20417424 within the TSS1500 of (alpha-N-acetyl-neuraminyl-2,3beta-galactosyl-1,3)-N-acetylgalactosaminide

alpha-2,6-sialyltransferase

5

(ST6GALNAC5), was associated with overall asthma, but not with either atopy-specific
strata. Yet, methylation levels at this site were associated with FEV1/FVC ratio, among
persons with and without atopy, and with BDR among persons without atopy. The
protein encoded by ST6GALNAC5 is involved in modifying cell-surface proteins,
influencing how they participate in cell-cell and cell-extracellular matrix interactions88.
The final two sites, cg25578728 within the body of chromodomain helicase DNA
binding protein 7 (CHD7) and cg19974715 [intergenic], were strongly associated with
asthma both among those with and without atopy. And, cg19974715 was also associated
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with BDR among persons with atopy. CHD7 encodes for a protein that is involved in
chromatin remodeling, and thus may have widespread affects on gene-expression. Recent
work with mouse models has shown that functional CHD7 is necessary for proper
craniofacial development and formation of the airways during development and in
humans may result in CHARGE syndrome89.
Although none of the above genes, which contained our 9 identified CpG sites
(within 100kb), have been previously implicated in studies of asthma, the roles that these
genes play in inflammation, cell surface protein modifications, development of the
respiratory tract, and peripheral airway restriction are all important mechanisms in
asthma pathogenesis. Thus these may represent some under-studied candidate genes and
CpG sites that could play important roles in asthma etiology. However, the above
findings must be interpreted within the limitations of this study.
Due to the cross-sectional design, measurements of DNA-M, asthma, spirometry,
and FeNO were all obtained at the same point in time; thus, temporality between DNA-M
and our different outcomes cannot be established. It is possible that these findings are a
product of reverse causation, in which the observed variations in DNA-M were actually
caused by asthma or asthma treatments. Follow-up studies with longitudinally collected
DNA-M levels and asthma assessments could provide more insight into which of these
variations might contribute to the development of asthma or the persistence of asthma,
and which may come about as a result of asthma. Also, some may consider the use of
questionnaire-based asthma determinations a limitation of this study. However, the
questions used in our diagnosis came from the validated ISAAC questionnaire5. Also,
despite the many different presentations of asthma, multiple studies have been successful
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at replicating findings using general asthma-status as an outcome, which may support that
there are some common molecular mechanisms driving the various asthmatic phenotypes.
Also, we found that eight of our nine sites were associated with asthma stratified by atopy
status and six of the nine sites were associated with airway obstruction (FEV1/FVC),
reversible airway obstruction (BDR), and/or airway hyper-reactivity (FeNO). Lastly,
although there were multiple functionally interesting genes identified in this study, we
only evaluated variations in DNA-M at the identified CpG sites. Thus it is unclear
whether the variations in DNA-M at these sites would result in any regulatory effect on
the expression of any of these genes. However, current paradigms indicate that
methylation within promoter regions typically leads to transcriptional silencing while
methylation within the gene-body is more frequently associated with increased
expression and alternative splicing32. Thus interesting follow-up work could involve
investigations into whether variations in DNA-M at these sites are associated with
corresponding variations in gene-expression, and if those variations in gene-expression
are related to the frequency and severity of asthmatic symptoms, FEV1/FVC, BDR, or
FeNO.
In conclusion, we found that DNA-M variations at nine novel CpG sites were
associated with prevalent asthma at age 18. For some of these sites, the association was
strongest among persons with atopy (cg16658191 in HK1, cg04359558 in LITAF, and
cg14727512 in DGCR14), some among persons without atopy (cg00100703 in UNC45B,
cg07948085 [intergenic], and cg01046943 in NUP210), while others were associated
with asthma regardless of their atopy status (cg25578728, cg01046943, and
cg19974715). We also found that cg00100703 in UNC45B was associated with
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FEV1/FVC and FeNO; cg07948085 [intergenic] was associated with FeNO; cg14727512
in DGCR14 was associated with FeNO; cg16658191 in HK1 was associated with BDR,
cg19974715 [intergenic] was associated with BDR; and cg20417424 in ST6GALNAC5
was associated with FEV1/FVC.
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Table 2.1: Comparison of lung function and cell-type distributions between those with
and without asthma in the overall epigenetic sub-sample.
Asthmatics
(n=51)

Non-Asthmatics
(n=319)

Asthma
Comparison
χ2
PStatistic
Value
0.054
0.816
23.811 < 0.001
TPStatistic
Value
-0.09 0.9307
1.78 0.0794
3.63 0.0006
-3.78 0.0004
-3.70 0.0005
-0.27 0.7907
-1.36 0.1755
1.58 0.1193
-2.21 0.0306
0.57 0.5676
-3.60 0.0007
1.74 0.0927
vital capacity; BDR,

Categorical
Factors
n
Percent
n
Percent
Female Sex 35
68.6
210
65.8
Atopy 33
66.0
93
29.5
Continuous
Factors
n
Mean (SD)
n
Mean (SD)
FVC 49 4.50 (0.874) 307
4.48 (0.857)
FEV1 49 3.74 (0.750) 307
3.94 (0.719)
FEV1/FVC Ratio 49 0.83 (0.088) 307
0.88 (0.064)
BDR 48 7.74 (6.243) 294
4.17 (4.802)
†
FeNO 47 21.00 (35.37) 300
14.0 (17.67)
CD8T 51 0.075 (0.081) 319
0.072 (0.048)
CD4T 51 0.133 (0.048) 319
0.123 (0.045)
Natural Killer Cells 51 0.073 (0.058) 319
0.087 (0.061)
B Cells 51 0.053 (0.022) 319
0.045 (0.025)
Monocytes 51 0.080 (0.026) 319
0.082 (0.024)
Eosinophils 51 0.043 (0.043) 319
0.021 (0.023)
Other Granulocytes 51 0.536 (0.107) 319
0.563 (0.100)
FEV1, forced expiratory volume in 1 second; FVC, forced
bronchodilator reversibility; FeNO, fractional-exhaled nitric oxide
†
Due to heavy positive skew of FeNO, medians were presented in the mean column, and
log(FeNO) was used for computing the T-test.
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Table 2.2: Comparison of stage 1 and stage 2 samples for asthma variables and cell
proportions.
Stage 1 Sample
(ns1=91)
Asthma Prevalence
Non-Asthmatic
Asthmatic
Lung Function
FVC
FEV1
FEV1/FVC Ratio

n
79
12
n
88
88
88

Stage 2 Sample
(ns2=279)

%
86.81
13.19

n
240
39

Mean (SD)
4.497 (0.801)
3.917 (0.688)
0.875 (0.075)

n
268
268
268

%
86.02
13.98
Mean (SD)
4.482 (0.877)
3.909 (0.739)
0.875 (0.068)

Sample
Comparison
ChiPStatistic
Value
0.0002
0.987
TStatistic
0.152
0.095
0.004

PValue
0.879
0.925
0.997

BDR
83 5.933 (5.085) 259 4.269 (5.141)
2.773
0.006
†
FeNO
83 14.00 (17.46) 264 15.00 (23.50)
-0.493
0.623
Cellular
TPHeterogeneity
n
Mean (SD)
n
Mean (SD)
Statistic
Value
CD8T
91 0.074 (0.055) 279 0.071 (0.053)
0.458
0.647
CD4T
91 0.128 (0.040) 279 0.123 (0.047)
1.006
0.316
Natural Killer
91 0.085 (0.052) 279 0.085 (0.064)
0.072
0.942
B Cells
91 0.049 (0.026) 279 0.045 (0.024)
1.093
0.276
Monocytes
91 0.080 (0.024) 279 0.082 (0.024)
-0.559
0.577
Eosinophils
91 0.021 (0.024) 279 0.025 (0.029)
-1.242
0.216
Other Granulocytes
91 0.555 (0.090) 279 0.561 (0.105)
-0.537
0.592
FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; BDR,
bronchodilator reversibility; FeNO, fractional-exhaled nitric oxide
†
Due to heavy positive skew of FeNO, medians were presented in the mean column, and
log(FeNO) was used for computing the T-test.
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Table 2.3: Stage 2 (ns2=279) – Crude logistic regression results for the sites within a 10%
FDR.
CpG ID
β1
P-Val. Q-Val. Gene
Gene Region
cg16658191 -1.90 0.00004 0.003
HK1
Body;1stExon
cg25578728 -1.83 0.00036 0.010
CHD7
Body
cg00100703 -1.68 0.00049 0.010
UNC45B
3'UTR
cg07948085 -1.49 0.00054 0.010
cg09241885 -1.02 0.00102 0.015
C20orf118
TSS200
cg11310939 -1.46 0.00120 0.015
MARCH3
5'UTR
cg01069468 -1.69 0.00231 0.025
SYNGAP1
Body
cg04359558 -1.03 0.00304 0.029
LITAF
Body
cg06866208 -1.44 0.00520 0.041
cg13753183 -1.66 0.00529 0.041
APTX
Body;1stExon;5'UTR
cg06648780 -1.29 0.00728 0.051
ALCAM
Body
cg24491618 -1.34 0.00961 0.062
KCNH2
Body
cg09597192 -1.23 0.01154 0.066
AGPAT1
5'UTR
cg15344640 -1.39 0.01234 0.066
LMAN2
Body
cg26252077 -0.93 0.01360 0.066
NFIA
Body
cg24368962 -1.17 0.01433 0.066
SIK2
Body
cg09278187 -1.24 0.01453 0.066
FOXJ3
3'UTR
cg20417424 -1.19 0.01610 0.068
ST6GALNAC5
TSS1500
cg10704177 -0.70 0.01690 0.068
INADL
5'UTR
cg14727512 1.53 0.01809 0.070
TSSK2;DGCR14 1stExon;3'UTR
cg08940169 -0.85 0.01908 0.070
ZFPM1
Body
cg01046943 1.75 0.02345 0.081
NUP210
Body
cg19974715 1.51 0.02415 0.081
cg19232164 -1.32 0.02681 0.086
REXO2
3'UTR
β1 = parameter estimate for the effect of DNA-M on asthma status
P-Val = p-value corresponding to the significance of β1
Q-Val = FDR-adjusted p-values, adjusted for 121 regression models
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Table 2.4: Pooled Sample (n=370) – Crude and adjusted ORs for M-values predicting
asthma status.
Model 1
Model 2
Model 3
Crud
Adj.*
Adj.*
CpG ID
e OR Crude CI
OR
Adj. CI
* OR
Adj. CI
cg16658191 0.098 (0.04, 0.23)
0.136
(0.04, 0.49)
0.129
(0.03,0.48)
cg19232164 0.098 (0.03, 0.28)
0.281
(0.07,1.04)
0.254
(0.06, 0.94)
cg13753183 0.109 (0.04, 0.31)
0.364
(0.08, 1.62)
0.347
(0.07,1.58)
cg25578728 0.116 (0.05, 0.28)
0.163
(0.06, 0.44)
0.109
(0.03,0.33)
cg01069468 0.118 (0.04, 0.31)
0.409
(0.09, 1.78)
0.486
(0.10,2.23)
cg00100703 0.120 (0.05, 0.28)
0.190
(0.07, 0.52)
0.177
(0.06,0.50)
cg06866208 0.137 (0.05, 0.34)
0.449
(0.11, 1.89)
0.532
(0.12,2.33)
cg24491618 0.143 (0.06, 0.35)
0.500
(0.12, 2.06)
0.550
(0.13,2.31)
cg15344640 0.148 (0.05, 0.39)
0.973
(0.19, 4.66)
1.095
(0.20,5.74)
cg11310939 0.155 (0.07, 0.34)
0.378
(0.10, 1.35)
0.434
(0.11,1.57)
cg06648780 0.157 (0.07, 0.36)
0.347
(0.09, 1.19)
0.365
(0.09,1.33)
cg07948085 0.157 (0.07, 0.34)
0.308
(0.11, 0.82)
0.280
(0.09,0.78)
cg09597192 0.158 (0.07, 0.37)
0.702
(0.16, 3.12)
1.010
(0.21,4.83)
cg20417424 0.170 (0.07, 0.40)
0.359
(0.12, 0.99)
0.353
(0.12,0.99)
cg24368962 0.174 (0.07, 0.39)
0.650
(0.16, 2.69)
0.489
(0.11,2.14)
cg09278187 0.176 (0.07, 0.44)
0.574
(0.16, 1.96)
0.674
(0.19,2.35)
cg04359558 0.233 (0.12, 0.42)
0.358
(0.18, 0.70)
0.352
(0.17,0.69)
cg08940169 0.265 (0.14, 0.50)
0.990
(0.29, 3.40)
1.158
(0.31,4.30)
cg26252077 0.277 (0.14, 0.53)
0.698
(0.25, 1.87)
0.710
(0.25,1.93)
cg09241885 0.286 (0.16, 0.49)
0.513
(0.22, 1.17)
0.447
(0.18,1.08)
cg10704177 0.340 (0.20, 0.57)
1.140
(0.39, 3.34)
1.608
(0.51,5.08)
cg14727512 7.997 (2.58, 26.09)
10.562 (3.12, 37.97) 10.464 (3.02,38.64)
cg01046943 9.464 (2.36, 39.32)
9.639
(2.25, 42.35) 9.626
(2.23,43.44)
cg19974715 9.516 (2.99, 31.59)
8.968
(2.63, 31.92) 8.785
(2.54,31.88)
OR, odds ratio; CI, 95% confidence interval; Adj., adjusted
* Odds ratios adjusted for potential confounders strongly associated with asthma status:
proportions of B-cells and eosinophils.
** Odds ratios adjusted for sex and overall cellular heterogeneity (proportions of CD8T
cells, CD4T cells, B-cells, monocytes, natural killer cells, eosinophils, and other
granulocytes). Sites whose 95% CIs didn’t cross the null are emphasized with bold text.
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Table 2.5: Crude and adjusted ORs for M-values predicting asthma status stratified by
atopy status, among the top nine sites.
Atopy (n= 126; 33 with asthma)
Crude OR Crude CI
Adj** OR Adj CI
cg16658191
0.10
(0.03,0.32)
0.09
(0.01,0.77)
cg25578728*
0.13
(0.03,0.43)
0.15
(0.02,0.82)
cg00100703
0.36
(0.07,1.61)
0.19
(0.06,0.58)
cg07948085
0.27
(0.05,1.19)
0.21
(0.07,0.56)
cg20417424
0.20
(0.03,1.06)
0.12
(0.03,0.41)
cg04359558
0.18
(0.07,0.41)
0.29
(0.10,0.81)
cg14727512
14.11
(2.71,86.41)
22.99
(3.43,194.38)
cg01046943
5.61
(0.74,45.72)
3.85
(0.39,40.55)
cg19974715*
20.76
(3.70,140.35)
26.32
(3.57,251.98)
No Atopy (n=239; 17 with asthma)
Crude OR Crude CI
Adj** OR Adj CI
cg16658191
0.23
(0.04,1.17)
0.18
(0.02,1.41)
cg25578728*
0.15
(0.04,0.62)
0.06
(0.01,0.35)
cg00100703
0.09
(0.02,0.36)
0.03
(0.01,0.19)
cg07948085
0.22
(0.05,0.85)
0.15
(0.02,0.89)
cg20417424
0.61
(0.14,2.53)
0.59
(0.11,2.88)
cg04359558
0.43
(0.15,1.15)
0.40
(0.13,1.16)
cg14727512
5.45
(0.83,39.75)
7.14
(1.18,46.99)
cg01046943
38.23
(4.20,390.06)
35.26
(3.32,444.37)
cg19974715*
7.06
(1.14,44.18)
8.32
(1.22,59.89)
OR, odds ratio; CI, 95% confidence interval; Adj., adjusted
* Sites that were significantly associated with asthma in both strata, after adjusting for
sex and cellular heterogeneity.
** Odds ratios adjusted for sex and overall cellular heterogeneity (proportions of CD8T
cells, CD4T cells, B-cells, monocytes, natural killer cells, eosinophils, and other
granulocytes). Sites whose 95% CIs didn’t cross the null are emphasized with bold text.
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Table 2.6: Parameter estimates from linear regressions for measures of airway obstruction (FEV1/FVC), hyper-reactivity (BDR) and
airway inflammation (FeNO) for the top 9 sites, stratified by atopy status.
FEV1/FVC
BDR
FeNO
Strata
Crude P-Val Adj* P-Val Crude P-Val Adj* P-Val Crude P-Val Adj** P-Val
Atopy
0.166 0.58 0.739 -0.37
0.04
0.031 0.01 0.627 -1.97
<0.001 -0.21
0.024
cg00100703
No Atopy 0.03
0.251 -0.25 0.790 -0.04
0.255 -0.02
0.650
0.003 0.03 0.032 -0.98
Atopy
-0.02
0.555 -0.03 0.486 2.43
0.365 1.13 0.680 0.21
0.203 0.17
0.253
cg01046943
No Atopy -0.03
0.191 -0.03 0.190 1.83
0.223 2.10 0.166 0.02
0.745 0.03
0.608
Atopy
0.01
0.317 -0.01 0.631 -1.14
0.219 0.32 0.772 -0.18
-0.04
0.484
0.002
cg04359558
No Atopy 0.01
0.153 0.01 0.558 0.62
0.328 1.10 0.103 0.00
0.958 0.01
0.645
Atopy
0.03
0.043 0.02 0.480 -3.13
0.007 -2.88 0.087 -0.38
<0.001 -0.20
0.028
cg07948085
No Atopy 0.02
0.179 0.01 0.649 0.87
0.322 1.54 0.138 -0.01
0.902 0.00
0.971
Atopy
-0.02
0.448 -0.03 0.262 1.62
0.436 1.20 0.574 0.25
0.060 0.32
0.005
cg14727512
No Atopy -0.01
0.547 -0.01 0.539 0.31
0.795 0.57 0.638 -0.08
0.146 -0.03
0.580
Atopy
0.336
0.04
0.021 0.05 0.135 -3.83
0.006 -4.91 0.036 -0.39
<0.001 -0.13
cg16658191
No Atopy 0.02
0.101 0.01 0.558 -0.49
0.654 -0.44 0.740 -0.05
0.366 0.01
0.859
Atopy
-0.04
0.215 -0.03 0.346 5.73
0.545 0.03
0.812
0.005 4.89 0.016 0.08
cg19974715
No Atopy -0.02
0.281 -0.01 0.365 -0.57
0.661 -0.93 0.479 0.04
0.499 0.00
0.955
Atopy
0.920
0.07
<0.001 0.05 0.022 -3.70
0.012 -1.63 0.361 -0.29
0.001 0.01
cg20417424
No Atopy 0.03
0.171 0.01
0.877
0.006 0.03 0.022 -2.18
0.020 -2.41 0.017 -0.06
Atopy
0.03
0.089 0.00 0.870 -1.91
0.176 0.78 0.665 -0.13
0.127 0.12
0.229
cg25578728
No Atopy 0.01
0.305 0.00 0.787 -1.23
0.185 -0.68 0.512 -0.07
0.100 -0.03
0.530
FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; BDR, bronchodilator reversibility; FeNO, fractional-exhaled
nitric oxide
* Parameter estimates adjusted for height, sex and overall cellular heterogeneity (proportions of CD8T cells, CD4T cells, B-cells,
monocytes, natural killer cells, eosinophils, and other granulocytes). Sites with P-values < 0.05 are emphasized with bold text.
** Parameter estimates adjusted for sex and overall cellular heterogeneity (proportions of CD8T cells, CD4T cells, B-cells,
monocytes, natural killer cells, eosinophils, and other granulocytes). Sites with P-values < 0.05 are emphasized with bold text.
CpG ID
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Table 2.7: Annotations and biological functions of genes associated with the nine CpG sites associated with asthma, independent of
cellular heterogeneity and sex.

CpG ID

Gene
Ch Region

Gene ID

Gene Name

42

Gene Description
Encodes a protein that is involved in
cg00100703 17 3'UTR
UNC45B
unc-45 homolog B
myoblast and sarcomere organization.
Encodes a protein that is a major
component in the nuclear pore complex,
cg01046943 3
Body
NUP210
Nucleoporin 210kDa
which controls the flow of molecules
between the nucleus and cytoplasm.
Lipopolysaccharide-Induced
Encodes a protein which promotes TNF-α
cg04359558 16 Body
LITAF
TNF-α Factor
factor expression.
cg07948085 10 N/A
Encodes a component of a spliceosome;
DiGeorge Syndrome Critical
cg14727512 22 3'UTR
DGCR14
deletions in this region associated with
Region Gene 14
DiGeorge syndrome.
Body;
Encodes a hexokinase involved in glucose
cg16658191 10
HK1
Hexokinase 1
1stExon
metabolism; associated with anemia.
cg19974715 17 N/A
(alpha-N-acetyl-neuraminylEncodes a protein that modifies cell2,3-beta-galactosyl-1,3)-Nsurface proteins that are important in cellcg20417424 1
TSS1500 ST6GALNAC5
acetylgalactosaminide alphacell or cell-extracellular matrix
2,6-sialyltransferase 5
interactions.
Encodes a protein that is involved in
Chromodomain Helicase DNA regulating gene-expression via chromatin
cg25578728 8
Body
CHD7
Binding Protein 7
remodeling and loss-of-function results in
CHARGE syndrome.
Ch, Chromosome; TSS1500, transcription start site within 1500 base pairs; UTR, untranslated region

Figure 2.1: Tracking of the misclassification rates (y-axis) across iterations (x-axis) of the
recursive RF feature selection.
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Figure 2.2: Histogram of P-values from 121 regressions in the stage 2 analyses.
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Figure 2.3: Comparison of parameter estimates from stage 1 and stage 2 logistic
regression models, among the 24 sites within a 10% FDR in stage 2 analyses.
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Figure 2.4: Correlation matrix of 9 CpGs associated with asthma, independent of cellular
heterogeneity, and cell predicted cell proportions.
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Figure 2.5: Correlation matrix of 15 CpGs associated with asthma, but confounded by
cellular heterogeneity.
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Figure 2.6: Cell and tissue morphology network, including seven genes with higher (red)
or lower (green) methylation levels associated with asthma status.
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CHAPTER 3
EXPLORATORY STUDY OF GENETIC AND EPIGENETIC VARIATIONS ASSOCIATED
WITH YOUNG ADULT WHEEZE CLUSTERS

3.1 Introduction:
Asthma and wheeze illness, defined by restricted airflow, encompass a wide array
of symptoms and physiological characteristics including allergic hypersensitivity,
impaired lung function and responsiveness to bronchodilators1. The frequency and
severity of these symptoms are somewhat dependent on the time of onset and gender, and
the combination of all these factors influence the management and prognosis of disease.
Recent studies have made use of clustering to classify persons with asthma and/or
wheeze based on clinical and demographic features such as race, gender, age of onset of
illness, atopic status, obesity, comorbidities, severity of disease, and lung function 4,90–92.
Previous work within the Isle of Wight (IOW) birth cohort , an unselected population
birth cohort in the United Kingdom, identified six distinct clusters of young adult
wheeze, characterized by 13 important components of wheezing illness in 18 year olds 4.
Each cluster represented a group of individuals with recent wheeze or asthma symptoms,
which were relatively homogeneous in gender, time of onset, allergic sensitivity, lung
function, and levels of treatment.
It has long been recognized that T-cell polarization towards a Th2 phenotype,
which drive pro-inflammatory responses, was an important cellular component of allergy
and allergic asthma15,93 and CD4+T cells tend to commit to type 2 helper (Th2) T
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cells in response to an allergen among persons with atopy8,94. A set of cytokines, referred
to collectively as the Th2 path, are largely responsible for Th2 commitment, have been
associated with asthma33,38,95. Although early work primarily indicated Th2-polarization
was important in allergic asthma, recent work has shown that Th2 cytokines are involved
in the pathogenesis of both allergic and non-allergic asthma3. The transcription factor
GATA-binding protein 3 (GATA3) is one of the most important regulator of Th2
cytokines3, and has been found to be up-regulated in both atopic and non-atopic asthma96.
Interleukin (IL)4 also drives naïve T cells towards a Th2 phenotype, while IL13 and IL4
both promote IgE production which is involved in allergy and allergic asthma3. The
similar functions of IL4 and IL13 are likely related to the fact that both have affinity for
the IL4 receptor (IL4Rα)97. Also, signal transducer and activator of transcription (STAT)6 and IL4R are upregulated among both atopic and non-atopic asthma, although both
appear to be more highly expressed in atopic asthma96. STAT6 expression is induced by
IL13 and IL4 activation of IL4Rα, and has consistently been associated with high IgE and
childhood asthma97. IL3, IL4 and STAT6 may also be involved the development of
airway airway and hypertrophy of smooth muscle98. Recent research has found that IL13,
but not IL4, may also be expressed from non-Th2 cells but still confer type-2-like
immune response99.
Genetic variations in IL495,100, IL4R100, IL1395, STAT6101, and GATA3102 genes
have previously been associated with asthma and allergic disease. More recently, DNAM variations within these genes (IL4, IL4R, IL13, STAT6, and GATA3)1,35,103,104 have
been associated T-cell polarization and/or risk of asthma. We have also shown that the
effects of DNA-M on risk of allergic disease can be dependent on genetic variations in
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SNPs35,36,103, and that risk of asthma and asthma transitions were associated with
interactions between CpG sites and SNPs in the Th2 pathway104. However, it is still
largely unknown whether such variations within this pathway lead to an overall
underlying asthma trait, or to specific clinical or physiological characteristics of asthma.
We hypothesized that persons with clinically similar asthma and wheezing illness
would share similar underlying genetic and epigenetic variations within the Th2 path. To
test this hypothesis, we compared DNA-M levels and genotypes among selected CpG
sites and SNPs within GATA3, STAT6, IL4, IL4R, and IL13 among those without wheeze
and those within young adult wheeze clusters. Furthermore, we aimed to identify whether
a subset of genetic and epigenetic variations that could most effectively distinguish
between young adult wheeze clusters.
3.2 Methods:
The Isle of Wight birth cohort
The Isle of Wight (IOW) birth cohort was established to study the natural history
of asthma and allergies in children born between January 1, 1989 and February 28, 1990
in Isle of Wight, UK. The study was approved by the local research ethics committee
(now named the National Research Ethics Service, NRES Committee South Central –
Southampton B, 06/Q1701/34) and written informed consent was provided by the infants’
parents. Details about the birth cohort have been described in detail elsewhere46,47. After
exclusion of adoptions, prenatal deaths and refusals, 1,456 children were enrolled, and
followed-up at 1 (n=1,167; 80.2%), 2 (n=1,174; 80.6%), 4 (n=1,218; 83.7%), 10
(n=1,373; 94.3%), and 18 (n=1,313; 90.2%) years of age. At each follow-up, participants
were administered detailed questionnaires and evaluated for manifestations of allergic
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disease. Questionnaires included the International Study of Asthma and Allergies in
Childhood (ISAAC)5 as well as study-specific questions about allergic disease and
relevant risk factors . Most of those who attended the follow-up visit in-person were also
assessed for spirometry, BDR, BHR, FeNO, and skin prick tests (SPTs). At the 18-year
follow-up, a random subset of participants was selected to take part in epigenetic
screening (n=368).
Dependent Variables
The primary dependent variable for young adult wheeze was a nominal variable
with five levels; the details of the clustering used to create this variable are described in
elsewhere4. Participants with asthma or wheezing illness at age 18 (n=309) were
clustered on 13 variables via k-means clustering. Six distinct clusters were identified.
Because cluster six (C6) was under-sampled during the random selection of the
epigenetic sub-sample (described below), we selected clusters one through five for
analysis in this study.
DNA Methylation
For epigenetic screening, blood samples were collected at the 18 year follow-up.
DNA was extracted from whole blood using a standard salting out procedure
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. DNA

concentration was determined by the PicoGreen dsDNA quantitation kit (Molecular
Probes, Inc., OR, USA). One microgram of DNA was bisulfite-treated for cytosine to
thymine conversion using the EZ 96-DNA methylation kit (Zymo Research, CA, USA),
following the manufacturer's standard protocol. Genome-wide DNA methylation was
assessed using the Illumina Infinium HumanMethylation450K BeadChip (Illumina, Inc.,
CA, USA), which interrogates >484,000 CpG sites, regions of DNA where a cytosine
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nucleotides are followed by a guanine nucleotide, associated with approximately 24,000
genes. The BeadChips were scanned using a BeadStation, and the methylation levels (
value, described below) were calculated for each queried CpG locus using the
Methylation Module of BeadStudio software. Arrays were processed using a standard
protocol as described elsewhere52, with multiple identical control samples assigned to
each bisulphite conversion batch to assess assay variability and samples were randomly
distributed on microarrays to control against batch effects.
Data Cleaning
The program for data cleaning was written in R (R Development Core Team,
2012). Quality control (QC) measures were employed to improve the reliability of data
prior to analysis. In our study, the detection P-value reported by BeadStudio (Illumina
software to process raw intensities) was used as a QC measure of probe performance.
Probes whose detection P-values > 0.01 in >10% of the samples were removed53. The
methylation data were then preprocessed and technical variations removed via peakcorrection using the Bioconductor IMA (Illumina methylation analyser) package55.
Dropping control probes and probes with poor detection P-values. The arrays were
processed in three different batches; batch number was recorded as a categorical variable
which was used in ComBat to adjust for inter-array variation54. Methylation levels for
each queried CpG were calculated as beta () values. These represent the proportions of
methylated probes for each specific CpG site and can be interpreted as percent
methylation.

53

SNP Assessments
We selected SNPs potentially related to asthma within five genes in the Th2
pathway (IL4, IL4R, IL13, GATA3, and STAT6). Genotyping was conducted on DNA
extracted from blood or saliva samples for 1,211 cohort subjects using GoldenGate
Genotyping Assays (Illumina, Inc., CA, USA), the details of which are reported
elsewhere36. In total, DNA methylation at 107 CpG sites and 42 SNPs were available: 72
CpGs and 17 SNPs in GATA3, 12 CpGs and 13 SNPs in IL4R, 9 CpGs and 7 SNPs in
IL13, 5 CpGs and 4 SNPs in IL4, and 9 CpGs and 1 SNP in STAT6.
Statistical Analyses
All statistical analyses were carried out in R. Due to the relatively small sample
size and large number of potential predictors, we used unsupervised data-reduction
techniques to reduce the number CpG sites and SNPs for analyses. For CpG sites, we first
explored potential outliers; observations that appeared to be erroneous or substantially
different from the distribution were recoded as missing. This resulted in 13 observations
within 11 CpG sites being recoded to missing. Then we selected the most variable sites
(standard deviation > 0.02), resulting in 21 CpG sites for analyses. For SNPs, we
identified linkage disequilibrium (LD) blocks using Haploview105, and only included
those SNPs that were not included in a block as well as one SNP from each block35,103 as
a representative for that block. When applicable, we preferentially included SNPs from
LD blocks that had been previously studied in relation to asthma, lung-function or
allergic disease.
We then explored whether methylation levels within GATA3 (10 CpGs), IL4R (3
CpGs), STAT6 (1 CpG), IL13 (5 CpGs), and IL4 (2 CpGs) varied by wheeze-clusters via
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ANOVA models. Prior to implementing the ANOVA models, we converted the
methylation β values into M-values via log2(β / (1-β)) which more closely approximate a
normal distribution57. We also explored whether genetic variation within GATA3 (8
SNPs), IL4R (9 SNPs), STAT6 (1 SNPs), IL13 (4 SNPs), and IL4 (2 SNPs) differed by
wheeze-cluster via χ2 tests. Then, to see whether there was consistency between wheeze
cluster associations and wheeze vs non-wheeze associations, we collapsed clusters of
wheeze (C1-C5) into a single group of persons with wheeze, and compared them to
persons without wheeze at the same 24 SNPs and 21 CpG sites, using χ2 tests and t-tests
respectively.
Lastly, among the SNPs and CpG sites that showed differential variations among
the wheeze clusters, we produced a conditional inference tree106 to explore whether a set
of genetic and epigenetic loci, rather than individual loci, may be more effective at
distinguishing between the different wheeze clusters. Many tree-based methods exist; we
chose to use conditional inference trees (CTREE) over classification and regression trees
(CART) or recursive partitioning and regression trees (RPART) because: 1) their variable
selection process is based on tests of statistical significance rather than information, and
2) their variable selection process is not biased towards selecting continuous predictors or
predictors with more possible cut-points107. Nonetheless, as with other tree-based
methods, conditional inference trees are biased towards correctly classifying the majority
class in a highly imbalanced dataset. To minimize this bias, we excluded persons without
wheeze at age 18 from our analysis.
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3.3 Results:
The five clusters represented unique combinations of physiologic, clinical, and
symptomatic characteristics (Table 3.1). Cluster 1 (C1) represented a childhood-onset
wheeze group with the best lung-function metrics. Cluster 2 (C2) was a childhood-onset
wheeze group with intermediate lung function metrics and intermediate proportions
allergic diseases. Cluster 3 (C3) was a mostly female, childhood-onset wheeze group with
high prevalence of allergic disease (atopy, rhinitis, and eczema), the most impaired lungfunction, and high BDR and FeNO. Cluster 4 (C4) was a mostly female, latest-onset
wheeze group with the low prevalence of atopy, and low BDR, IgE and FeNO. Cluster 5
(C5) was a mostly female, late-childhood onset wheeze group with normal lung-function
and intermediate allergic disease prevalence.
Due to the small sample sizes within each cluster, we reduced the number of tests
performed on SNPs by identifying blocks of SNPs in LD analyses. Then we only
performed analyses on one SNP per block as well as SNPs outside of LD-blocks (Figure
3.1, Figure 3.2, and Figure 3.3), resulting in 24 SNPs for analyses. In univariate results
(Table 3.2), only one SNP (rs1058240) showed significant variation across the six groups
(P-value = 0.0075), although this finding was not robust under Bonferroni adjustment for
24 tests (α = 0.002). For these analyses, GG and AG were analyzed together as one class
since there were only 9 participants with GG genotype, all of which were among those
without wheeze. The clusters ‘C2’ and ‘C3’ had the highest proportions of GG/AG
(52.6% and 71.4% respectively). Cluster ‘C5’, had the lowest proportion of GG/AG
(9.1%). Clusters ‘C1’ and ‘C4’ had proportions of GG/AG (35.7% and 37.5%%
respectively) similar to those without any wheeze at age 18 (32.7%).
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We also reduced the number of CpG sites for analyses by only selecting the most
variable CpGs (those with a standard deviation ≥ 0.02), resulting in 21 CpG sites for
analyses. In univariate results (Table 3.3), seven CpG sites showed significant variation
across the six groups: cg25368824 in the TSS200 of IL4 (P-value = 0.00005),
cg12377972 in the 5’UTR of IL4 (P-value = 0.049), cg06584121 in the TSS200 of IL13
(P-value = 0.0032), cg131993853 also in the TSS200 of IL13 (P-value = 0.0031), as well
as three CpG sites with the body of GATA3 cg12181459 (P-value = 0.024), cg25630514
(P-value = 0.023), and cg00463367 (P-value = 0.00029). Only cg25368824 and
cg00463367 survived the Bonferroni adjustment for 21 tests (α = 0.0024).
Among persons without wheeze at age 18 as a reference group, cluster ‘C4’ had
the most unique epigenetic pattern. We found that cluster ‘C4’ was consistently different
from those free of wheeze; it had significantly higher methylation at cg25368824 (Pvalue = 0.0063), and significantly lower methylation levels at cg06584121 (P-value =
0.0010), cg06967316 (0.0015), cg1218159 (P-value = 0.0015), cg25630514 (P-value =
0.0013) and cg00463367 (P-value = 0.00004).
Then we tested whether a set of the nominally significant (P-values < 0.05) CpGs
and/or SNPs could distinguish between the five clusters of participants with wheeze using
conditional inferences trees (Figure 3.4). We found that two predictors could significantly
distinguish some, but not all, clusters. Among persons with wheeze, those with
methylation levels ≤ 0.579 at cg25630514 (P-value = 0.019) were most likely to belong
to cluster 4 (47%), whereas those with methylation > 0.579 at cg25630514 were most
likely to belong to cluster 5 (51%) if they also had genotype AA at rs1058240 and most
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likely to belong to cluster 2 (46%) if they had genotype GG or AG at rs1058240 (P-value
= 0.021).
Last, we investigated whether the same CpG sites and SNPs identified in the
above analyses would have been identified if our outcome variable were a dichotomous
measure of person with wheeze (combined C1-C5, n=75) vs. persons without wheeze at
age 18 (n=293). Only one CpG site was found to have differential methylation between
person with and without wheeze, whereas 3 SNPs were found to have differential genetic
variation. Average methylation at cg12377972 within IL4 was lower among persons with
wheeze compared to those without wheeze (mean and standard deviation = 0.906 (0.02)
vs 0.913 (0.02), respectively; T-test P-value = 0.031). Three other SNPs, all within IL4R,
did show nominal variation between those with and without wheeze. At rs1110470,
persons with wheeze were less likely to have the minor allele compared to those without
wheeze, AA (16.4% vs 23.7%, respectively) or AG (44.8% vs 52.6%, respectively) (χ2 Pvalue = 0.04). At rs3024604, persons with wheeze were more likely than those without to
have the minor allele GG or AG (23.2% vs 21.1%, respectively; χ2 P-value = 0.03).
Lastly, at rs8832, persons with wheeze were more likely than person without wheeze (χ2
P-value = 0.04) to be homozygous for the minor allele AA (32.4% vs 19.1%,
respectively), similar for heterozygous AG (43.7% vs 47.7%, respectively), and less
likely to be homozygous for the major allele GG (23.9% vs 33.2%, respectively).
3.4 Discussion:
We found that there were epigenetic variations at three CpGs (cg12181459,
cg25630514, and cg00463367) in the body of GATA3, one CpG (cg25368824) within 200
base pairs (bp) of the transcription start site (TSS200) of IL4, one CpG (cg12377972)
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within the 5’ untranslated region (5’UTR) of IL4, and two CpG (cg06584121 and
cg06967316) within the TSS200 of IL13, as well as genetic variation at one SNP
(rs1058240) within the 3’UTR of GATA3 that were dependent on the type of wheeze as
determined by clustering on 13 clinical characteristics. Only cg25368824 and
cg00463367 maintained statistical significance after Bonferroni-adjustment for multiple
testing.
We also observed greater epigenetic variation when comparing the clusters to
each other (7 CpG sites and 1 SNP were nominally significant) and greater genetic
variation when comparing those with and without wheeze overall (3 SNPs and 1 CpG site
were nominally significant). Additionally, only cg12377972 was statistically significant
in both analyses, likely because those without wheeze had the highest methylation levels,
while all of the wheeze clusters had varying levels of methylation but all lower than that
of the non-wheeze group. For all other nominally significant sites, some wheeze clusters
had higher average methylation when compared to non-wheeze while others had lower
average methylation. These findings support the idea that asthma and wheeze are
heterogeneous diseases with different symptomatic profiles which may result from
various unique pathophysiology2.
The cluster (C4) characterized by being mostly female, late-onset wheeze with
low prevalence of allergic diseases and low levels for BDR, FeNO and serum IgE, was
most different from the other clusters across the epigenetic loci. We did not have
expression of these genes, but could assume that epigenetic regulation of expression at
the nominally significant CpG sites follows the common paradigm: DNA-M is negatively
correlated with expression in promotors and positively correlated with expression in gene
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bodies32. Then we would expect persons in this cluster to have lower expression of IL4,
higher expression of IL13, and lower expression of GATA3. IL4, IL13, and GATA3 all
promote Th2 differentiation108,109, but differ somewhat in their activities. GATA3 is often
referred to as the master regulator of Th2 differentiation, as it is a transcription factor that
up-regulates the production of other pro-Th2 cytokines110. Though IL4 and IL13 are
structurally similar and share the same receptor (IL4R), IL4 appears to be more important
in the polarization of Th2 phenotype, while IL13 plays its role in the effector phase109.
There is also new research showing that while IL13 and IL4 are both produced in Th2
cells, but only IL13 is produced from type-2 innate lymphoid cells (ILC2)110, a cell type
that has only recently been implicated and asthma and allergic disease99. Despite
relatively few studies of the activity of ILC2s in humans, they have been suggested to
play a role in both Th2-like asthma and severe asthma99.
This has important implications for generalizing findings or for conducting
validation studies of wheeze-illness in independent samples. As suggested by
others18,26,27, the ability to replicate a finding likely depends on whether the asthmatics
being studied have similar distributions of many characteristics (e.g., time of onset,
measures of lung function, bronchial reactivity, amount of treatment being taken, and
prevalence of allergic sensitization).
Interestingly, our main finding among SNPs (rs1058240) has received some
attention in previous studies of allergic disease. Within the IOW this SNP was associated
with rhinitis and allergic rhinitis111 while others observed that increasing frequency of the
minor allele was associated with decreased allergic sensitization and that presence of the
major allele (G) was associated with susceptibility for asthma and atopic asthma (Slager
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2010). More recently, Yang et al. showed that rs1058240 is at the binding site for three
different microRNAs (miRNA), and that genetic variations at this SNP were associated
with differential GATA3 expression, where AA variants had significantly higher
expression when compared with either AG or GG variants112. This could be an example
of genetic (SNP) and epigenetic (miRNA) interaction influencing disease. Interesting
follow-up work could investigate the combined influence of miRNA expression, GATA3
expression, and polymorphisms at rs1058240, on various wheeze phenotypes.
These findings should be interpreted within the limitations of this study. This
work was exploratory, and the observed associations are limited in their generalizability
but should new hypotheses for further investigation. One limitation was the use of kmeans clustering on 13 characteristics to define the outcome variable. This would be
difficult to reproduce within an independent cohort due to variations in such
characteristics across populations. Second, the clusters within our epigenetic sample had
small sample sizes (minimum cluster sample size = 7), and thus may not be very
representative of persons with similar characteristics. Future studies in larger samples
would provide stronger evidence on whether variations in Th2-path genes are indeed
variable by sets of multiple physiologic, clinical and symptomatic characteristics.
Because this analysis involved a sub-sample of the original data, we compared average
levels and proportions of the clinical characteristics among persons with wheeze in our
epigenetic sub-sample (n=75) to those in the full cohort (n= 279). Overall, the sub-sample
was no different from the full sample for proportions of females, or prevalence of rhinitis,
eczema, or atopy (χ2 P-values > 0.05), as well as for average measures of FEV1, FVC,
FEV1/FVC, FEF2575, BDR, FeNO, total IgE, BTS Step, or age of onset (T-test P-values
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> 0.05), so it is unlikely that selection of the epigenetic sub-sample biased the observed
associations. Despite these limitations, we believe follow-up investigations of these
findings are warranted given that phenotypic-heterogeneity of asthma, and the likely
corresponding heterogeneity of underlying mechanisms, has been long recognized but
often studied with individual characteristics of wheeze-illness rather than overall wheeze
phenotype based on multiple characteristics. These findings suggest that using a complex
outcome variable, such as young adult wheeze clusters, may lead to new findings but it is
still unclear whether those findings can be generalizable and offer clinical utility.
In summary, we found that DNA-M varied based on different wheeze-illness
phenotypes at cg25630514 in the body of GATA3 and at cg25368824 in the TSS200 of
IL4, suggesting that epigenetic regulation of these cytokines differs among persons with
wheeze that have different physiologic, clinical and symptomatic characteristics. We also
found that genetic variation at rs1058240 in the 3’UTR of GATA3, which is at the binding
site for several miRNAs, differed among persons with different wheeze phenotypes.
Given that this study was exploratory, these associations should be investigated in
independent study populations.
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Table 3.1: Prevalence and average values of physiologic, clinical, and symptomatic
characteristics of the five wheeze clusters (n=75).
C1 (n=14)
C2 (n=20)
C3 (n=7)
C4 (n=9)
C5 (n=25)
Categorical Factors
n (%)
n (%)
n (%)
n (%)
n (%)
Female
7 (50.0)
12 (60.0)
6 (85.7)
8 (88.9)
18 (72.0)
Rhinitis
12 (85.7)
10 (50.0)
7 (100.0)
5 (55.6)
12 (48.0)
Eczema
3 (21.4)
3 (15.0)
2 (33.3.0)
1 (11.1)
3 (12.0)
Atopy
12 (85.7)
9 (45.0)
6 (100.0)
2 (25.0)
12 (48.0)
Continuous Factors
Mean (SD)
Mean (SD)
Mean (SD)
Mean (SD)
Mean (SD)
FEV1
4.57 (0.85)
3.58 (0.77)
3.33 (0.82)
3.12 (0.35)
3.96 (0.75)
FVC
5.14 (1.10)
4.74 (1.10)
4.50 (0.84)
3.88 (0.35)
4.29 (0.62)
FEV1/FVC 0.90 (0.10)
0.77 (0.11)
0.74 (0.08)
0.81 (0.12)
0.92 (0.11)
FEF25:75
4.93 (0.62)
3.47 (0.61)
2.5 (0.84)
3.62 (0.52)
5.00 (1.35)
BDR
4.57 (1.96)
6.96 (3.63)
12.45 (3.79)
2.76 (3.78)
2.62 (1.73)
FeNO
64.29 (34.22) 26.22 (28.93) 64.33 (22.61) 13.38 (5.63) 26.17 (35.71)
Serum IgE 810.2 (780.3) 217.5 (342.5) 439.0 (237.6) 84.8 (31.4) 257.1 (535.8)
BTS Step
2.29 (0.95)
1.86 (0.69)
2 (0.71)
1.33 (0.58)
1.83 (0.75)
Onset of
6.36 (5.53)
4.53 (4.65)
5 (3.85)
14.56 (2.35) 10.22 (5.84)
Wheeze
FEV1: Forced expiratory volume (L) in one second (s).
FVC: Forced vital capacity (L).
FEV1/FVC: Ratio of FEV1 to FVC.
FEF25-75%: Forced expiratory flow 25-75% (L/s).
BDR: Bronchodilator reversibility; percent change in FEV1 post-salbutamol (600mg)
challenge.
FeNO: Log10 of fractional exhaled nitric oxide (ppb).
Serum IgE: Log10 of total IgE.
BTS Step: British Thoracic Society step of therapy (0-4), higher values reflect higher
levels of treatment.
Onset of Wheeze: Age (in years) when wheeze first appeared.
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Table 3.2: Proportions of genetic variants among selected Th2 SNPs within young adult wheeze clusters.
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SNP Annotations
GATA3
SNPs
Genotype
AAorAG
rs2229359
GG
AA
rs3802604 AG
GG
AA
rs568727
AC
CC
AAorAT
rs3802600
TT
AA
rs422628
AG
GG
GGorAG
rs1058240
AA
AAorAG
rs434645
GG
AA
rs12412241 AG
GG

Total
n (%)
47 (13.5%)
302 (86.5%)
144 (42.1%)
149 (43.6%)
49 (14.3%)
34 (10.5%)
142 (43.7%)
149 (45.8%)
115 (33.1%)
232 (66.9%)
196 (56.3%)
134 (38.5%)
18 (5.2%)
114 (33.3%)
228 (66.7%)
98 (28.6%)
245 (71.4%)
33 (9.6%)
138 (40%)
174 (50.4%)

Wheeze-free
n (%)
41 (14.6%)
239 (85.4%)
111 (40.7%)
121 (44.3%)
41 (15%)
30 (11.6%)
111 (43%)
117 (45.3%)
97 (35.1%)
179 (64.9%)
156 (56.3%)
105 (37.9%)
16 (5.8%)
89 (32.7%)
183 (67.3%)
73 (26.8%)
199 (73.2%)
30 (10.9%)
106 (38.5%)
139 (50.5%)

Comparing genetic variation across 6 groups
C1
C2
C3
C4
n (%)
n (%)
n (%)
n (%)
0 (0%)
1 (5.6%)
2 (28.6%) 1 (12.5%)
14 (100%) 17 (94.4%) 5 (71.4%) 7 (87.5%)
4 (28.6%) 10 (52.6%) 1 (14.3%)
6 (75%)
8 (57.1%)
7 (36.8%) 4 (57.1%) 1 (12.5%)
2 (14.3%)
2 (10.5%) 2 (28.6%) 1 (12.5%)
1 (7.7%)
1 (5.6%)
1 (16.7%)
0 (0%)
8 (61.5%)
8 (44.4%) 4 (66.7%) 2 (28.6%)
4 (30.8%)
9 (50%)
1 (16.7%) 5 (71.4%)
6 (42.9%)
2 (10.5%) 3 (42.9%)
2 (25%)
8 (57.1%) 17 (89.5%) 4 (57.1%)
6 (75%)
8 (57.1%)
9 (47.4%) 3 (42.9%) 5 (62.5%)
6 (42.9%)
9 (47.4%) 4 (57.1%) 3 (37.5%)
0 (0%)
1 (5.3%)
0 (0%)
0 (0%)
5 (35.7%) 10 (52.6%) 5 (71.4%) 3 (37.5%)
9 (64.3%) 9 (47.4%) 2 (28.6%) 5 (62.5%)
5 (35.7%)
9 (47.4%) 4 (57.1%)
2 (25%)
9 (64.3%) 10 (52.6%) 3 (42.9%)
6 (75%)
0 (0%)
1 (5.3%)
0 (0%)
1 (12.5%)
4 (28.6%)
9 (47.4%) 5 (71.4%) 5 (62.5%)
10 (71.4%) 9 (47.4%) 2 (28.6%)
2 (25%)

C5
n (%)
P-Val.
1 (4.8%)
0.28
20 (95.2%)
12 (60%)
8 (40%)
0.16
0 (0%)
0 (0%)
9 (40.9%)
0.46
13 (59.1%)
5 (22.7%)
0.19
17 (77.3%)
15 (68.2%)
7 (31.8%)
0.95
0 (0%)
2 (9.1%)
0.0075
20 (90.9%)
4 (18.2%)
0.15
18 (81.8%)
1 (4.8%)
8 (38.1%)
0.53
12 (57.1%)

Table 3.2: Proportions of genetic variants among selected Th2 SNPs within young adult wheeze clusters (cont’d).
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SNP Annotations
IL4R
SNPs
Genotype
AA
rs2057768 AG
GG
AA
rs1110470 AG
GG
GGorAG
rs3024604
AA
CC
rs3024622 CG
GG
GGorAG
rs4787423
AA
CCorCA
rs1805011
AA
AA
rs8832
AG
GG
AAorAG
rs12102586
GG
AA
rs16976728 AG
GG

Total
n (%)
23 (6.6%)
151 (43.1%)
176 (50.3%)
75 (22.3%)
172 (51%)
90 (26.7%)
49 (14.3%)
293 (85.7%)
38 (11.6%)
140 (42.8%)
149 (45.6%)
78 (22.3%)
271 (77.7%)
74 (21.4%)
272 (78.6%)
76 (21.8%)
163 (46.8%)
109 (31.3%)
59 (16.9%)
290 (83.1%)
64 (18.4%)
152 (43.7%)
132 (37.9%)

Wheeze-free
n (%)
15 (5.4%)
122 (43.7%)
142 (50.9%)
64 (23.7%)
142 (52.6%)
64 (23.7%)
33 (12.1%)
240 (87.9%)
28 (10.6%)
114 (43.3%)
121 (46%)
61 (21.9%)
217 (78.1%)
60 (21.7%)
216 (78.3%)
53 (19.1%)
132 (47.7%)
92 (33.2%)
44 (15.8%)
234 (84.2%)
51 (18.3%)
118 (42.4%)
109 (39.2%)

Comparing genetic variation across 6 groups
C1
C2
C3
C4
n (%)
n (%)
n (%)
n (%)
1 (7.1%)
4 (21.1%)
0 (0%)
0 (0%)
7 (50%)
8 (42.1%) 3 (42.9%) 1 (12.5%)
6 (42.9%)
7 (36.8%) 4 (57.1%) 7 (87.5%)
2 (14.3%)
4 (21.1%) 1 (14.3%)
2 (25%)
7 (50%)
8 (42.1%) 4 (57.1%) 5 (62.5%)
5 (35.7%)
7 (36.8%) 2 (28.6%) 1 (12.5%)
3 (21.4%)
4 (21.1%) 2 (28.6%)
2 (25%)
11 (78.6%) 15 (78.9%) 5 (71.4%)
6 (75%)
1 (7.7%)
5 (29.4%)
0 (0%)
0 (0%)
8 (61.5%)
7 (41.2%)
3 (50%)
3 (37.5%)
4 (30.8%)
5 (29.4%)
3 (50%)
5 (62.5%)
3 (21.4%)
4 (21.1%) 3 (42.9%) 1 (12.5%)
11 (78.6%) 15 (78.9%) 4 (57.1%) 7 (87.5%)
3 (21.4%)
4 (22.2%) 2 (28.6%) 1 (12.5%)
11 (78.6%) 14 (77.8%) 5 (71.4%) 7 (87.5%)
5 (35.7%)
9 (47.4%) 1 (14.3%) 1 (12.5%)
7 (50%)
5 (26.3%) 5 (71.4%)
4 (50%)
2 (14.3%)
5 (26.3%) 1 (14.3%) 3 (37.5%)
5 (35.7%)
3 (15.8%) 1 (14.3%)
2 (25%)
9 (64.3%) 16 (84.2%) 6 (85.7%)
6 (75%)
2 (14.3%)
5 (27.8%)
0 (0%)
1 (12.5%)
7 (50%)
7 (38.9%) 6 (85.7%) 3 (37.5%)
5 (35.7%)
6 (33.3%) 1 (14.3%)
4 (50%)

C5
n (%)
3 (13.6%)
10 (45.5%)
9 (40.9%)
2 (11.1%)
5 (27.8%)
11 (61.1%)
4 (20%)
16 (80%)
4 (21.1%)
5 (26.3%)
10 (52.6%)
5 (22.7%)
17 (77.3%)
4 (18.2%)
18 (81.8%)
7 (31.8%)
10 (45.5%)
5 (22.7%)
4 (18.2%)
18 (81.8%)
5 (22.7%)
11 (50%)
6 (27.3%)

P-Val.
0.19

0.19
0.21
0.28
0.85
0.99
0.16
0.45
0.69

Table 3.2: Proportions of genetic variants among selected Th2 SNPs within young adult wheeze clusters (cont’d).
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SNP Annotations
STAT6
Total
Wheeze-free
SNPs
Genotype
n (%)
n (%)
52 (18.6%)
GGorAG
66 (19%)
rs1059513
227 (81.4%)
AA
282 (81%)
IL4R
Total
Wheeze-free
SNPs
Genotype
n (%)
n (%)
96 (34.7%)
CCorAC
119 (34.2%)
rs1881457
181 (65.3%)
AA
229 (65.8%)
97 (34.9%)
AAorAG
121 (34.9%)
rs1800925
181
(65.1%)
GG
226 (65.1%)
99 (35.5%)
AAorAG
119 (34.1%)
rs20541
180 (64.5%)
GG
230 (65.9%)
50 (17.9%)
AAorAG
63 (18.1%)
rs2243204
229 (82.1%)
GG
286 (81.9%)
IL4R
Total
Wheeze-free
SNPs
Genotype
n (%)
n (%)
73 (26.4%)
AAorAG
84 (24.3%)
rs2070874
204 (73.6%)
GG
262 (75.7%)
54 (19.5%)
GGorCG
64 (18.4%)
rs2243263
223 (80.5%)
CC
284 (81.6%)
SNP, single nucleotide polymorphism; C1, cluster 1; C2,
Fisher’s Exact test.

Comparing genetic variation across 6 groups
C1
C2
C3
C4
C5
n (%)
n (%)
n (%)
n (%)
n (%)
P-Val.
4 (28.6%)
5 (26.3%)
0 (0%)
1 (14.3%) 3 (14.3%)
0.65
10 (71.4%) 14 (73.7%) 7 (100%) 6 (85.7%) 18 (85.7%)
C1
C2
C3
C4
C5
n (%)
n (%)
n (%)
n (%)
n (%)
P-Val.
5 (35.7%)
8 (42.1%) 2 (28.6%)
2 (25%)
6 (27.3%)
0.94
9 (64.3%) 11 (57.9%) 5 (71.4%)
6 (75%)
16 (72.7%)
6 (42.9%)
9 (47.4%) 2 (28.6%) 1 (12.5%)
6 (30%)
0.60
8 (57.1%) 10 (52.6%) 5 (71.4%) 7 (87.5%)
14 (70%)
3 (21.4%)
6 (31.6%) 2 (28.6%) 3 (37.5%) 6 (28.6%)
0.92
11 (78.6%) 13 (68.4%) 5 (71.4%) 5 (62.5%) 15 (71.4%)
2 (14.3%)
6 (31.6%) 1 (14.3%) 1 (12.5%) 3 (14.3%)
0.75
12 (85.7%) 13 (68.4%) 6 (85.7%) 7 (87.5%) 18 (85.7%)
C1
C2
C3
C4
C5
n (%)
n (%)
n (%)
n (%)
n (%)
P-Val.
3 (21.4%)
2 (10.5%) 1 (14.3%) 2 (28.6%) 3 (14.3%)
0.57
11 (78.6%) 17 (89.5%) 6 (85.7%) 5 (71.4%) 18 (85.7%)
2 (14.3%)
3 (15.8%) 2 (28.6%) 1 (12.5%)
2 (9.1%)
0.81
12 (85.7%) 16 (84.2%) 5 (71.4%) 7 (87.5%) 20 (90.9%)
cluster 2; C3, cluster 3; C4, cluster 4; C5, cluster 5; P-Val., p-value from a

Table 3.3: Average DNA-M levels among selected Th2 CpGs within young adult wheeze clusters.
CpG Annotations

Mean (sd) within each wheeze cluster¥

CpG
Wheeze-free
P-val.€
C1 (n=14) C2 (n=20) C3 (n=7)
Location
(n=293)
cg25368824 TSS200 0.00005 0.86 (0.02)
0.84 (0.05) 0.85 (0.04) 0.82 (0.04)
IL4
5'UTR;
cg12377972
0.049
0.91 (0.02)
0.90 (0.03) 0.90 (0.02) 0.89 (0.03)
1stExon
cg26937798 5'UTR
0.15
0.08 (0.02)
0.08 (0.02) 0.07 (0.03) 0.07 (0.02)
IL4R
cg16649560 5'UTR
0.076
0.19 (0.05)
0.17 (0.03) 0.17 (0.05) 0.18 (0.03)
cg01165142 Body
0.42
0.69 (0.05)
0.69 (0.05) 0.70 (0.05) 0.71 (0.05)
cg04303330 TSS1500 0.82
0.29 (0.04)
0.29 (0.04) 0.29 (0.05) 0.29 (0.03)
cg13566430 TSS1500 0.63
0.20 (0.03)
0.19 (0.02) 0.19 (0.02) 0.18 (0.03)
IL13
cg06584121 TSS200 0.0033 0.89 (0.02)
0.89 (0.01) 0.89 (0.02) 0.88 (0.02)
cg06967316 TSS200 0.0032 0.84 (0.02)
0.83 (0.02) 0.83 (0.03) 0.84 (0.02)
cg11798521 3'UTR
0.52
0.83 (0.02)
0.83 (0.02) 0.83 (0.02) 0.84 (0.01)
cg17124583 Body
0.11
0.04 (0.02)
0.05 (0.02) 0.06 (0.02) 0.04 (0.02)
cg12181459 Body
0.023
0.39 (0.06)
0.41 (0.07) 0.40 (0.05) 0.40 (0.05)
cg11430077 Body
0.16
0.11 (0.04)
0.12 (0.04) 0.12 (0.05) 0.12 (0.04)
cg22770911 Body
0.79
0.52 (0.05)
0.54 (0.03) 0.52 (0.05) 0.51 (0.04)
cg10163955 Body
0.13
0.74 (0.05)
0.75 (0.04) 0.75 (0.05) 0.71 (0.05)
GATA3
cg04492228 Body
0.33
0.19 (0.04)
0.19 (0.04) 0.19 (0.04) 0.18 (0.04
cg17489908 Body
0.37
0.25 (0.04)
0.24 (0.04) 0.25 (0.05) 0.25 (0.04)
cg22892607 Body
0.073
0.06 (0.02)
0.07 (0.02) 0.07 (0.02) 0.08 (0.04)
cg25630514 Body
0.023
0.67 (0.06)
0.69 (0.07) 0.66 (0.08) 0.67 (0.03)
cg00463367 Body
0.00029 0.19 (0.05)
0.22 (0.05) 0.20 (0.06) 0.21 (0.05)
0.91
0.94 (0.01)
0.94 (0.02) 0.93 (0.02) 0.93 (0.02)
STAT6 cg07926491 3'UTR
€
ANOVA models used methylation M-values to test for significance of DNA-M variations.
¥
The mean and sd (standard deviation) were calculated using methylation β-values.
Gene

CGs

C4 (n=9)

C5 (n=25)

0.88 (0.02) 0.87 (0.03)
0.91 (0.01) 0.91 (0.02)
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0.05 (0.01)
0.24 (0.07)
0.72 (0.09)
0.31 (0.04)
0.20 (0.02)
0.86 (0.02)
0.81 (0.05)
0.82 (0.02)
0.04 (0.01)
0.32 (0.07)
0.08 (0.02)
0.53 (0.04)
0.76 (0.08)
0.22 (0.08)
0.28 (0.06)
0.06 (0.01)
0.58 (0.10)
0.13 (0.06)
0.94 (0.02)

0.07 (0.02)
0.18 (0.04)
0.69 (0.04)
0.30 (0.04)
0.20 (0.03)
0.90 (0.01)
0.85 (0.02)
0.83 (0.02)
0.04 (0.02)
0.39 (0.07)
0.11 (0.03)
0.51 (0.04)
0.74 (0.04)
0.18 (0.03)
0.24 (0.04)
0.06 (0.02)
0.66 (0.05)
0.18 (0.03)
0.93 (0.02)

Figure 3.1: LD Plot for GATA3
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Figure 3.2: LD Plot for IL4R
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Figure 3.3: LD Plot for IL4 and IL13.
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Figure 3.4: Conditional inference tree for classifying wheeze clusters with CpGs and
SNPs that were nominally significant via ANOVA and Fisher’s Exact Tests.
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CHAPTER 4
CORD BLOOD EXPRESSION LEVELS OF THE NOVEL GENES, HK1 AND LITAF,
PREDICT WHEEZE WITHIN FIRST OF LIFE

4.1 Introduction:
Wheeze, defined as a high-pitched whistle associated with narrowing of the
airways, is common among infants113 and it is often the defining symptom of asthma at
any age. However, many of the mechanisms which make infants particularly susceptible
to wheeze, including a more compliant chest wall as well as differences in smooth muscle
tone and tracheal cartilage composition, tend to improve as they grow older113. Thus,
most infant wheeze resolves within the first year after birth, with the majority of these
infants not being affected by asthma or recurrent wheeze later in life114. However, given
that wheezing is an indicator of narrow or obstructed airways at any age, there are
undoubtedly similarities between infant wheeze, particularly that which occurs without
colds, and later-life wheezing-illnesses such as asthma115. In fact, childhood wheeze
unrelated to cough or cold is an important criteria in the asthma predictive index (API), as
well as later modifications of the API, which use parental and early-life characteristics to
predict childhood diagnosis of asthma116. Thus, it is important to not only identify which
phenotypic presentations of infant wheeze are predictive of later life asthma, but also to
identify molecular mechanisms that are involved in both infant and later-life wheeze
illnesses, as these may help us to distinguish which infants with wheeze are more likely
to be affected by wheezing illnesses beyond infancy.
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It is recognized that persons affected by asthma and wheeze-illness often have
markers of immune dysregulation at birth, suggesting that prenatal factors likely
contribute to the differences in immune-programming that predispose certain individuals
to the development of asthma117. The intrauterine environment likely influences the
development of the fetal immune system118 as well as modeling of the fetal airways given
that pre-term and low birthweight babies are more likely to experience wheeze and/or
develop asthma119. Previous studies have shown that cytokine levels in cord blood are
associated with risk of wheeze or allergy in infancy and early childhood120. For instance,
infants with lower levels of production of interleukin (IL)-13121, IL-10 and interferon
(IFN)-γ122 at birth were more likely to develop atopic diseases during infancy or
childhood

121

while higher levels of IL-4 and IFN-γ have been associated with decreased

risk123 and higher levels of IL-8 with increased risk120 of asthma and wheeze in early
childhood. Most of these cytokines are involved in influencing T-helper (Th)-1 or Th-2
cell differentiation. However, it is likely that the expression of other genes involved in
asthma and wheeze could be identified in cord blood as predictors of infant wheeze.
Recently, we identified nine novel CpG sites that were differentially methylated
in association with asthma at age 18 years in an epigenome-wide association study, seven
of which were within novel genes (unpublished data): (alpha-N-acetyl-neuraminyl-2,3beta-galactosyl-1,3)-N-acetylgalactosaminide

alpha-2,6-sialyltransferase

5

(ST6GALNAC5), DiGeorge Syndrome Critical Region Gene 14 (DGCR14), Nucleoporin
210kDa (NUP210), Chromodomain Helicase DNA Binding Protein 7 (CHD7),
Lipopolysaccharide (LPS) Induced TNF-α Factor (LITAF), unc-45 homolog B
(UNC45B), and Hexokinase 1 (HK1). However, it was unclear whether the expression of
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these genes was related to asthma and/or wheeze, and whether DNA-M at the identified
CpG sites were functionally related to the expression of those genes. For the present
study, we hypothesized that cord blood expression levels of these genes may predispose
infants to wheeze within the first year of life, which is an early life risk factor for later
being diagnosed with asthma. We also hypothesized that the expression of these genes
would be correlated with DNA-M levels at the previously identified CpG sites:
cg20417424 within 1500 base pairs (bp) of the transcription start sites (TSS1500) of
ST6GALNAC5, cg14727512 within the three prime untranslated-region (3’UTR) of
DGCR14, cg01046943 within the body of NUP210, cg25578728 within the body of
CHD7, cg04359558 within the body of LITAF, cg00100703 within the 3’UTR of
UNC45B, and cg16658191 within the 1st exon of HK1. Therefore, in the present study we
investigated whether the expression levels of these seven genes were associated with
wheeze within the first 12 months of life in the IOW Third Generation cohort.
4.2 Methods:
The Isle of Wight birth cohort
The Isle of Wight (IOW) birth cohort was established to study the natural history
of asthma and allergies in children born between January 1, 1989 and February 28, 1990
in Isle of Wight, UK. Ethical approval was obtained from the Isle of Wight Local
Research Ethics Committee (now named the National Research Ethics Service, NRES
Committee South Central—Southampton B) for the 18 years follow-up (06/Q1701/34)
and NRES Committee South Central—Hampshire B (09/H0504/129) for the third
generation study. Details about the birth cohort have been described in detail
elsewhere46,47. The offspring of the original IOW birth cohort were recruited into the
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Third Generation study, and were followed up at 3 months, 6 months and 12 months after
birth. Genome-wide gene-expression and DNA-M levels were obtained from cord blood
samples at birth. Information on wheeze and maternal smoking was obtained via
questionnaires that were administered to parents of the infants at scheduled follow-up
visits. Data on sex, birthweight, gestational age, birth date, and type of delivery were
abstracted from medical records. Infants included in this study had information about
wheeze during at least one of the infant follow-up visits, and were non-missing for geneexpression and DNA-M for all of the selected mRNA and CpG probes (n=80).
Dependent Variables
The primary dependent variable for this study, wheeze, was a dichotomous
variable defined as wheeze when the infant did not have a cough or cold, during at least
one of the 3 infant follow-up visits. This was measured by an affirmative response to
“Has your child had wheezing or whistling in the chest?” as well as an affirmative
response to “Does your child wheeze in between cold or chest infection?”, reported at
any of the 3 month, 6 month, or 12 month post-birth follow-up visits. Three alternate
definitions of wheeze were utilized for sensitivity analyses. Any-wheeze was defined as
wheeze (whether or not associated with a cough or cold) reported at any of the infant
follow-up visits. Wheeze-frequency was defined as the number of follow-up periods
during which an infant experienced wheeze (when the infant did not have a cough or
cold). Any-wheeze-frequency was defined as the number of follow-up periods during
which an infant experienced any-wheeze (whether or not associated with a cough or
cold).
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Gene Expression Arrays
At birth, cord blood samples were collected with PAXgene RNA kits. RNA
integrity was verified with the Agilent 2100 Bioanalyzer system. Genome-wide mRNA
expression was assessed via one color (Cy3) experiments with the Agilent (Agilent
Technologies, Santa Clara, CA) SurePrint G3 Human Gene Expression 8x60k v2
microarray kits. Array content was sourced from RefSeq, Ensembl, UniGene, and
GenBank databases and provides full coverage of the human transcriptome in 50,599
biological features (including replicate probes and control probes). The oligos were
60mer in length and each transcript was tagged at least once and some had multiple
tagging oligos for genes with documented splice variants. Data QC indices and analyses
were performed with Agilent GeneSpring software.
For this study we selected a set of seven candidate probes measuring the
expression of genes (Accession IDs): NUP210 (NM_024923), HK1 (NM_033500),
ST6GALNAC5 (NM_030965), LITAF (NM_004862), CHD7 (NM_017780), UNC45B
(NM_173167), and DGCR14 (NM_022719).
DNA Methylation
Blood samples for epigenetic screening were collected at birth from the cord
blood; DNA was extracted using a salting out procedure described elsewhere51. DNA
concentration was determined by the PicoGreen dsDNA quantitation kit (Molecular
Probes, Inc., OR, USA). One microgram of DNA was bisulfite-treated for cytosine to
thymine conversion using the EZ 96-DNA methylation kit (Zymo Research, CA, USA),
following the manufacturer's standard protocol. Genome-wide DNA methylation was
assessed using the Illumina Infinium HumanMethylation450K BeadChip (Illumina, Inc.,
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CA, USA), which interrogates >484,000 CpG sites, regions of DNA where a cytosine
nucleotides are followed by a guanine nucleotide, associated with approximately 24,000
genes. The BeadChips were scanned using a BeadStation, and the methylation levels (
value, described below) were calculated for each queried CpG locus using the
Methylation Module of BeadStudio software. Arrays were processed using a standard
protocol as described elsewhere52, with multiple identical control samples assigned to
each bisulphite conversion batch to assess assay variability and samples were randomly
distributed on microarrays to control against batch effects.
Data Cleaning
The program for data cleaning was written in R (R Development Core Team,
2012). Quality control (QC) measures were employed to improve the reliability of data
prior to analysis. In our study, the detection P-value reported by BeadStudio (Illumina
software to process raw intensities) was used as a QC measure of probe performance.
Probes whose detection P-values > 0.01 in >10% of the samples were removed53. The
methylation data were then preprocessed and technical variations removed via peakcorrection using the Bioconductor IMA (Illumina methylation analyser) package55. The
arrays were processed in six different batches; batch number was recorded as a
categorical variable which was used in ComBat to adjust for inter-array variation54.
Methylation levels for each queried CpG were calculated as beta () values. These
represent the proportions of methylated probes for each specific CpG site and can be
interpreted as percent methylation. For this study we selected a set of candidate probes
we identified in a genome-wide DNA-M study for physician diagnosed asthma, that were
within the body or regulatory region of the genes listed above (unpublished data):
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cg00100703, cg01046943, cg04359558, cg14727512, cg16658191, cg20417424, and
cg25578728.
Statistical Analyses
All statistical analyses were carried out in R, with statistical significance
determined at an α of 0.05. Testing for differences in sex, type of delivery, maternal
smoking and season of birth, between infants with and without wheeze, were done via χ2
tests. Testing for differences in birth weight, gestational age and predicted cell-type
proportions, between infants with and without wheeze, were done via T-tests. Robust
regressions, which minimize the effects of outliers on the parameter estimates and
standard errors, were fit to test for associations between mRNA transcripts and other
variables. Robust logistic regression models were used to test the associations between
expression levels of the seven mRNA transcripts and infant wheeze. Robust poisson
regression models were used to test the associations between the seven mRNA transcripts
and infant wheeze frequency; only infants that were non-missing for all three infant
follow-up visits were included in these models. Robust linear regression models were
used to test the associations between expression of each mRNA transcript and DNA-M at
that gene’s selected CpG site.
Signed weighted correlation networks of gene-expression between the seven
mRNA transcripts were produced with the WGCNA package in R124,125. A soft threshold
power of three and minimum-module size of two were used to identify whether the seven
genes belonged to different modules. Eigengenes were produced to summarize the overall
expression of each module. Pairwise spearman correlations were produced to describe
how well each gene was represented by its corresponding eigengene. To observe whether
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a particular module was associated with infant wheeze, we produced multivariable
logistic regression models with infant wheeze as the outcome, module eigengenes as the
predictors, and sex, season of birth, and predicted cell-proportions as adjustment
covariates.
4.3 Results:
Infants in the IOW third generation study (n=80) consisted of similar proportions
of males (47.5%) and females (52.5%), typically born in spring months of April, May or
June (31.2%), primarily with normal delivery (69.2%), of normal average gestational age
(mean = 39.4 weeks std = 1.6), and normal average birth weight (mean = 3482.4g std =
531.3) (Table 4.1). In our sample, 76.3% of infants never experienced wheeze during the
first year of life, while 23.7% experienced wheeze during at least one infant follow-up
period. We then compared the distribution of a priori identified confounders between
infants that experienced wheeze to those that did not. There were no significant
differences in sex, season of birth, or predicted cell-type proportions from cord blood
samples. We also compared whether characteristics of the pregnancy or the infants atbirth that have been implicated as predictors of infant wheeze, such as cesarean
delivery126, maternal smoking at pregnancy119,127, gestational age (pre-term birth)119, and
birthweight128 differed between infants with and without wheeze. We observed no
statistically significant differences in type of delivery, maternal smoking during
pregnancy, gestational age, or birthweight.
Among these infants, we tested whether gene-expression was associated with
infant wheeze for seven candidate genes, within which DNA-M levels were previously
identified as markers of young adult prevalent asthma (unpublished data). Robust logistic
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regression models (Table 4.2) revealed that increased expression levels of HK1 in cord
blood were associated with increased risk of infant wheeze (β1 = 1.114, P-value = 0.027).
Although sex, season of birth, and predicted cell-proportions were not significantly
associated with wheeze (Table 4.1), we adjusted for these in our models as they were
identified a priori as potential confounders. Even after adjustment for sex, season of
birth, and cell-type proportions, greater expression of HK1 (β1 = 1.80, P-value = 0.030)
significantly increased the risk of infant wheeze, whereas lower expression of LITAF (β1
= -1.563, P-value = 0.047) was associated with increased risk of infant wheeze. Also,
lower expression of NUP210 was associated with infant wheeze after adjusting for sex
and month of birth (β1 = -2.106, P-value = 0.037), but adjusting for cord blood cellmixture eliminated this association. Cord blood expression of ST6GALNAC5, CHD7,
UNC45B, and DGCR14 were not associated with infant wheeze (P-values > 0.05).
Our primary analyses included infants that were evaluated for wheeze during at
least one of the three infant follow-up visits. However, those that attended all three
follow-ups had greater opportunity to report wheeze. To evaluate the potential bias of
missing follow-up visits, we conducted the same analyses as above, but only included
those (n=61) that had answered the questionnaire for all three follow-up visits (45
without infant wheeze and 16 with infant wheeze). After excluding those with any
missing assessments for wheeze, high HK1 expression was still significantly associated
with increased risk of wheeze (P-value = 0.049) and low LITAF expression was still
significantly associated with increased risk of wheeze (P-value = 0.014) (Table 4.3).
These findings suggest that missing one or two infant follow-ups did not substantially
bias the observed associations.
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Infant wheeze can also be transient, and recurrent wheeze, whether or not
associated with a cough or cold, has been shown to increase the risk of being diagnosed
with asthma later in life
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. Thus we also tested for associations between the expression

of HK1 and LITAF with wheeze-frequency (45 never experienced wheeze, 9 experienced
wheeze during one follow-up period, and 7 experienced wheeze during two-or-more
follow-ups) and any-wheeze-frequency (27 never experienced any-wheeze, 11
experienced any-wheeze during one follow-up period, 17 experienced any-wheeze during
two follow-u periods, and 6 experienced any-wheeze during all three follow-up periods).
However, lower levels of expression of LITAF were significantly associated with
increased wheeze-frequency (P-value = 0.010) and any-wheeze frequency (P-value =
0.006), while higher levels of expression of HK1 were marginally associated with
increased wheeze-frequency (P-value = 0.071) and significantly associated with anywheeze-frequency (P-value = 0.007). We produced box plots to visualize the distribution
of expression by any-wheeze-frequency. A dose-response relationship between HK1
expression and any-wheeze frequency was not obvious (Figure 4.1), whereas LITAF
expression does have an apparent inverse dose-response relationship with any-wheezefrequency (Figure 4.2).
We then investigated whether there were linear associations between geneexpression of the seven selected genes and DNA-M levels at the selected CpG sites. Only
one CpG probe was significantly associated with that gene’s expression levels: higher
methylation levels at cg16658191, which is within the first exon (or body), were
associated with decreased expression of HK1 (β1 = -5.92 P-value = 0.049; adjusted for
sex and month of birth). Also of note, higher DNA-M levels at cg14727512, which is
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within the first exon (or 3’UTR), were marginally associated with increased expression of
DGCR14 (β1 = 6.21 P-value = 0.089; adjusted for sex and month of birth). The linear
associations for the five other CpG-gene pairs were not even marginally significant (Pvalues > 0.10) indicating that these DNA-M sites were not involved in the up- or downregulation of the expression of the genes they are within, at least not in cord blood.
We then investigated the expression patterns among the seven selected genes;
pairwise correlations indicated that some of these genes may not be independently
expressed in cord blood (Table 4.4). Nine of the 21 pairwise correlations had P-values <
0.05, though most correlations were low-to-moderate (ρ < 0.50). Only CHD7 and
NUP210 had at least a moderate-to-strong correlation (ρ = 0.50 P-value < 0.0001). Given
the correlation structure among these seven genes, we explored whether a set (or sets) of
correlated genes could be represented by eigengenes, and whether those eigengenes were
predictive of infant wheeze. We identified two modules of genes with correlated geneexpression via weighted gene co-expression network analysis (WGCNA). Six of the
seven genes were moderately-to-strongly correlated (0.40 rho < 1.0 with P-values <
0.0001) with the eigengene of either module (Table 4.5), while HK1 did not fit within
either module. Eigengene 1 was primarily representative of the expression levels of
ST6GALNAC5 (ρ = 0.82) and UNC45B (ρ = 0.74). Eigengene 2 was representative of
NUP210 (ρ = 0.80), CHD7 (ρ = 0.73), DGCR14 (ρ = 0.54), and LITAF (ρ = 0.49). The
eigengene values for these two modules plus the expression of HK1, the combination of
which summarizes the overall variations across all seven genes, were then tested in
association with infant wheeze in a multiple logistic regression model. After adjusting for
sex, season of birth, and cell mixture, eigengene 2 was significantly associated with
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infant wheeze (βE2 = -7.19 P-value = 0.039) while HK1 was marginally associated (βHK1
= -6.76 P-value = 0.064) and eignengene 1 was not associated (P-value = 0.28) with
infant wheeze. Also of note, in a multivariate poisson regression model that was adjusted
for the same covariates, eigengene 2 was associated with wheeze frequency (βE2 = -5.88
P-value = 0.0045), while HK1 and eigengene 1 were not (P-values = 0.70 and 0.14
respectively).
So, taking all results together, the expression of HK1 was the strongest individual
predictor of infant wheeze, after adjusting for sex, season of birth, and cell-mixture.
However, when considering the expression of all seven genes, the overall expression of
DGCR14, NUP210, CHD7, and LITAF, as represented by eigengene 2, was the strongest
predictor of infant wheeze and wheeze frequency.
4.4 Discussion:
To the best of our knowledge, this was the first study to investigate whether cord
blood expression levels of ST6GALNAC5, DGCR14, NUP210, CHD7, LITAF, UNC45B,
or HK1 were associated with infant wheeze. We found that high levels of HK1 and low
levels of LITAF in cord blood were related to risk of wheeze and any-wheeze-frequency
in the first year of life, independent of sex, season of birth, and cellular heterogeneity
within the cord blood sample. We also found that low levels of NUP210 were associated
with increased risk of infant wheeze, though this association appeared to be driven by
differences in cellular heterogeneity and not a significant predictor after adjusting for
cell-type proportions. Cord blood expression levels of the four other genes tested
(UNC45B, ST6GALNAC5, DGCR14, and CHD7) were not significant predictors of infant
wheeze. Also of note, other potential predictors of infant wheeze that are established at or
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before birth (type of delivery, maternal smoking during pregnancy, gestational age, and
birthweight) were not associated with infant wheeze in our sample, suggesting that HK1
and LITAF may be unique predictors of infant wheeze without cough or cold. These
findings provide insight into previously unstudied molecular risk factors of infant
wheeze. Also, since infant wheeze is an early life risk factor for later being diagnosed
with asthma, and DNA-M variations at these sites have been associated with asthma at
age 18, these findings may provide a potential link between infant wheeze and young
adult asthma.
Although the expression of LITAF and HK1 were identified as novel predictors of
infant wheeze in the present study, previous work has characterized some of their
biological functions which are suggestive for how they may influence wheeze. Genetic
variations within HK1 have been associated with retinitis pigmentosa129 and congenital
hyperinsulinism130. Also, increased expression of HK1 has been observed in tumor cells
131

and HIV-infected macrophages132 which helps to stabilize the mitochondrial

membrane allowing those cells to avoid apoptosis72, but has never previously been
observed in association with infant wheeze. Yet, its functional roles make a biologically
plausible link to wheeze-illness. The lifespan of pro-inflammatory cells, such as
neutrophils, can be regulated via apoptotic signals and delayed response to such signals
has been associated with inflammatory disease133; for instance, neutrophils of asthmatics
appear to be resistant to CCL2-induced apoptosis134.
The functions of LITAF have primarily been studied in mechanistic animal
models, and it has been shown to form a complex with STAT6B, then translocate into the
nucleus resulting in the upregulation of multiple inflammatory cytokines79. LITAF and/or
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STAT6B also promote the expression of VEGF is known to promote angiogenesis in the
airways as well as the proliferation and differentiation of bronchial endothelial cells135,136
and T-cells137. TNF-α is an important pro-inflammatory cytokine, and SNPs within TNFα have been associated with asthma and wheeze, which may mediate the risk of maternal
smoking during pregnancy for wheeze or asthma138. Finally, LITAF has been suggested
to play a role in p53-dependent apoptosis139,140 and treatment with Cipangopaludina
chinensis-derived LITAF (CcLITAF) induced apoptosis in a human lung cancer cell
line141. Overall, LITAF can promote apoptosis and is an up-stream regulator of both
VEGF79 and TNF-α139, which influence multiple immune processes. Thus, the
dysregulation of the expression of LITAF may play critical roles in inflammation,
immune-cell-differentiation, angiogenesis and apoptosis, providing plausible links
through which LITAF may make important, yet under-studied molecular contributions to
wheezing among infants.
We also found that lower levels of DNA-M at cg16658191 within the 1st exon of
HK1 were associated with increased expression of HK1. This provides evidence that
methylation at this site may serve as a transcriptional repressor of this gene, though this
should be validated in an experimental design. Given that DNA-M can be stable over
time28, HK1 epigenetic-programming at or before birth could prospectively influence the
risk of wheeze over the first year of life and possibly later in life. Previously we observed
that low levels of DNA-M at cg16658191 were associated with higher probability of
having prevalent asthma at age 18 (unpublished data), and in the present study we have
observed that low levels of DNA-M at the same CpG site were associated higher
expression of HK1, and higher expression of HK1 was predictive of infant wheeze.
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We understand that our findings should be considered within the limitations of
this study. First, the candidate genes were selected due to previously identified DNA-M
associations in these genes with asthma at age 18. Although variations in DNA-M have
been shown to have functional relationships to gene-expression, this relationship can be
complex and sometimes inconsistent. Many factors other than DNA-M can increase or
decrease the expression of a particular gene: chromatin remodeling factors, histone
modifications, micro RNA activity, and transcription factor binding. Thus, it is possible
that the previously identified DNA-M associations would not result in changes in geneexpression that could then be associated with infant wheeze. Also, infant wheeze is a
common condition that often resolves in infancy or early childhood114 and is likely quite
distinct from young adult wheeze and asthma. Thus, gene-activity related infant wheeze
may not be the same as gene-activity related to asthma at age 18. These differences may
explain the lack of association between expression of DGCR14, UNC45B, CHD7, and
ST6GALNAC5 infant wheeze. We may not have accounted for all confounders, which
could have resulted in some residual confounding. Lastly, due to the small sample size in
the present study, these findings should be confirmed in an independent cohort with a
large sample.
Despite these limitations, this study was strong in many ways. First, its
prospective nature eliminates the possibility of reverse causation for the observed
associations. Second, we were able to adjust for cellular heterogeneity of the cord blood
samples, despite the inability to collect blood cell differentials due to logistical
constraints. Instead we utilized genome-wide DNA-M data to estimate the relative
proportions of major leukocyte components (B-cells, NK cells, CD4+T cells, CD8+T
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cells, monocytes, eosinophils, and other granulocytes)67. The inclusion of cellproportions in our statistical models allowed us to identify whether differences in geneexpression were merely acting as markers of different cellular compositions, as appears
to be the case with NUP210 in our sample. However, we understand that this method of
predicting cell-type proportions also has its limitations. This method is currently the goldstandard for predicting cell-type proportions from DNA-M and has been utilized in cord
blood samples previously142, though the algorithm’s accuracy has only been validated in
adult blood samples as of yet68. The adjusted analyses rely on the assumption that the
algorithm performs as well with cord blood samples as it has with adult blood samples.
To ensure that our top findings were not driven by any bias that may have been
introduced by this limitation, we produced the adjusted regression models with and
without cell-proportions as adjustment covariates (Table 2; Columns 3 and 2,
respectively). Our two main findings (HK1 and LITAF) were not affected by these
adjustments; however NUP210 was no longer a significant predictor of infant wheeze.
Thus we emphasized the more conservative models, those adjusted for of estimated celltype proportions, for our top findings.
In summary, we found that higher expression of HK1 and lower expression of
LITAF in cord blood were predictive of infant wheeze, and that the expression of HK1
may be regulated by DNA-M at cg16658191. Of greatest interest are the parallels that
can be drawn between our findings and the evidence in the literature suggesting that upregulation of HK172,132 and down-regulation of LITAF140,141 may both have anti-apoptotic
effects; combined with the evidence that anti-apoptotic effects in pro-inflammatory cells
results in prolonged inflammation133 and have been associated with asthma134. Thus our
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observations of higher HK1 and lower LITAF in cord blood as predictors of infant
wheeze may represent an anti-apoptotic predisposition for certain infants to experience
wheeze within the first year of life.
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Table 4.1: Distribution of risk factors for infant wheeze and asthma, stratified by infant
wheeze occurring apart from a cough or cold.

Variables
Infant Sex
Male
Female
Season of Birth
Jan/Feb/Mar
Apr/May/Jun
Jul/Aug/Sep
Oct/Nov/Dec
Cell-Mixture
CD8+T
CD4+T
Natural Killers
B-Cells
Monocytes
Eosinophils
Other Granulocytes
Delivery Type
Normal
Cesarean
Other
Smoke During
Pregnancy
No
Yes
Gestational Age
Weeks of Gestation
Birth Weight
Birth Weight (grams)

n (%)
38 (47.5)
42 (52.5)
n (%)
19 (23.8)
25 (31.2)
19 (23.8)
17 (21.2)
mean (sd)
0.057 (0.031)
0.134 (0.044)
0.059 (0.046)
0.109 (0.034)
0.108 (0.022)
0.049 (0.035)
0.506 (0.095)
n (%)
54 (69.2)
16 (20.5)
8 (10.3)

No Wheeze
w/o cough/cold
(n=61)
n (%)
28 (45.9)
33 (54.1)
n (%)
13 (21.3)
22 (36.1)
12 (19.7)
14 (23.0)
mean (sd)
0.059 (0.028)
0.132 (0.038)
0.053 (0.038)
0.106 (0.029)
0.108 (0.022)
0.046 (0.028)
0.516 (0.076)
n (%)
44 (73.3)
11 (18.3)
5 (8.3)

Wheeze
w/o cough/cold
(n=19)
n (%)
10 (52.6)
9 (47.4)
n (%)
6 (31.6)
3 (15.8)
7 (36.8)
3 (15.8)
mean (sd)
0.049 (0.039)
0.142 (0.059)
0.076 (0.064)
0.116 (0.046)
0.106 (0.022)
0.061 (0.050)
0.473 (0.138)
n (%)
10 (55.6)
5 (27.8)
3 (16.7)

n (%)

n (%)

n (%)

50 (64.1)
28 (35.9)
mean (sd)
39.4 (1.6)
mean (sd)
3482.9 (531.3)

40 (67.8)
19 (32.2)
mean (sd)
39.5 (1.5)
mean (sd)
3481.2 (522.2)

10 (52.6)
9 (47.4)
mean (sd)
39.2 (1.9)
mean (sd)
3488.9 (576.3)

Overall
(n=80)
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P-value
χ2 Test
0.80
χ2 Test
0.19

T-test
0.27
0.46
0.16
0.37
0.66
0.23
0.21
2
χ Test
0.34

χ2 Test
0.36
T-test
0.57
T-test
0.96

Table 4.2: Logistic regression results for cord blood gene-expression predicting wheeze
within the first year of life.
Crude
Adjusted*
Adjusted**
Gene
β1
P-value
β1
P-value
β1
P-value
-1.024
0.219
-0.585
0.596
-2.106
0.037
NUP210
1.114
0.027
1.319
0.020
1.800
0.030
HK1
0.207
0.625
0.380
0.492
0.372
0.587
ST6GALNAC5
-0.741
0.108
-1.222 0.032
-1.563 0.047
LITAF
-0.729
0.274
-1.146
0.129
-0.876 0.319
CHD7
-0.471
0.312
-0.841 0.134
-0.765 0.236
UNC45B
-0.959
0.183
-1.346 0.086
-1.594 0.103
DGCR14
*
Adjusted for sex and month of birth.
**
Adjusted for sex, month of birth and cell mixture (predicted proportions of CD4+T
cells, monocytes, natural killer cells, B cells, eosinophils, and other granulocytes).
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Table 4.3: Results from sensitivity analyses (excluding those with missing follow-up) and
frequency of wheeze within the first year of life.
Wheeze¥

Wheeze¥,**,*

WheezeFrequency¥,*
β1
P-value
1.368
0.071
-1.489
0.010

Any-WheezeFrequency¥¥,*
β1
P-value
0.737
0.007
-0.818
0.006

Gene
β1
P-value
β1
P-value
HK1
1.800
0.030
1.619
0.049
LITAF -1.563
0.047
-2.693
0.014
¥
Wheeze unrelated to a cough or cold.
¥¥
Wheeze whether or not related to a cough or cold.
*
Only included infants that evaluated for wheeze at all three infant follow-up visits
(n=61).
**
Because of the small number of cases and large number of adjustment covariates, this
model could not be fit with robust logistic regression and instead a standard logistic GLM
was used.
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Table 4.4: Spearman pairwise-correlation matrix of gene-expression levels in cord blood
(n=80).
Rho
(P-value)
ST6GALNAC5
HK1
LITAF
UNC45B

ST6GALNAC5
-

HK1
0.04
(0.74)
-

LITAF
-0.09
(0.43)
-0.09
(0.45)
-

UNC45B
0.26
(0.02)
-0.19
(0.08)
0.27
(0.02)
-

DGCR14
NUP210
CHD7
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DGCR14
-0.18
(0.11)
-0.26
(0.02)
0.17
(0.14)
-0.01
(0.95)
-

NUP210
-0.18
(0.10)
-0.09
(0.44)
0.23
(0.04)
0.29
(<0.01)
0.27
(0.01)
-

CHD7
-0.39
(<0.01)
-0.22
(0.04)
0.17
(0.15)
0.21
(0.06)
0.22
(0.06)
0.50
(<0.01)
-

Table 4.5: Pairwise correlations between gene-expression levels and eigengene values.
Rho (P-value)
ST6GALNAC5
DGCR14
NUP210
CHD7
LITAF
UNC45B
HK1

Eigengene 1
0.82 (< 0.0001)
-0.13 (0.24)
0.04 (0.74)
-0.14 (0.20)
0.07 (0.52)
0.74 (< 0.0001)
-0.09 (0.41)

Eigengene 2
-0.29 (0.007)
0.54 (< 0.0001)
0.80 (< 0.0001)
0.73 (< 0.0001)
0.49 (< 0.0001)
0.34 (0.003)
-0.24 (0.03)
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HK1
0.04 (0.74)
-0.26 (0.02)
-0.09 (0.43)
-0.22 (0.05)
-0.09 (0.45)
-0.19 (0.08)
1 (< 0.0001)

Figure 4.1: Distribution of HK1 expression levels by any-wheeze-frequency.
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Figure 4.2: Distribution of LITAF expression levels by any-wheeze-frequency.
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CHAPTER 5
CONCLUSIONS AND FINAL REMARKS
Overall, this dissertation achieved its objectives by exploring genetic and
epigenetic variations in the Th2-path associated with complex wheeze phenotypes (Aim
2), identified novel epigenetic loci whose DNA-M levels were associated with physician
diagnosed asthma (Aim 1), and related the expression of the genes encompassing the
novel epigenetic loci to infant wheeze (Aim 3).
Summary of Findings and Innovations (Aim 1 and Aim 3):
From our genome-wide DNA-M association study, we found that nine epigenetic
loci were differentially methylated in association with prevalent asthma at age 18:
cg25578728 in the body of CHD7, cg16658191 in the 1st exon of HK1, cg00100703 in
the 3’UTR of UNC45B, cg07948085 [intergenic], cg04359558 in the body of LITAF,
cg20417424 in the TSS1500 of ST6GALNAC5, cg19974715 [intergenic], cg01046943 in
the body of NUP210 and cg14727512 in the 3’UTR of DGCR14. Interestingly, even
though these were strongly associated with physician diagnosed asthma, they appear to
drive different underlying aspects of asthma. For instance, DNA-M in HK1, LITAF,
DGCR14 were more strongly associated with atopic asthma, DNA-M in NUP210 and
UNC45B were more strongly associated with non-atopic asthma, whereas DNA-M within
CHD7 was associated with both atopic and non-atopic asthma. We also observed varying
degrees of association between the nine sites with lung function (FEV1/FVC), BDR, and
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FeNO. These findings suggest that DNA-M at these nine sites influence different
physiologic mechanisms which may influence asthma. For GWAS, replication has been a
gold-standard for eliminating false-positives, overfitting, and other biases30; thus, a
replication study in an independent cohort is currently underway.
We then hypothesized that if the seven genes associated with our Aim 1 findings
represented true underlying mechanisms that contribute to asthma, some of these genes
could be differentially expressed in cord blood in association with infant wheeze. We
found that the expression levels of both HK1 and LITAF were associated with risk of
experiencing wheeze within the first year of life. Also, HK1 expression shared an inverse
linear relationship with DNA-M levels at cg16658191 whereas expression of LITAF was
not linearly associated with DNA-M levels at cg04359558.
We did not have data on gene-expression in the young adults, so we compared our
findings in Aim 1 with Aim 3 via currently accepted paradigms for how DNA-M relates
to gene-expression. DNA-M in the promoter region or the 1st exon is consistently
associated with transcriptional repression, yet DNA-M within the gene-body is most
frequently associated with promotion of transcription 32. Assuming these paradigms hold
true, then low DNA-M at cg04359558 (body) is a marker of low expression of LITAF
and low DNA-M at cg16658191 (1st exon) is a marker of high expression of HK1, both
of which were associated with increased odds of prevalent asthma at age 18. The
relationships between expected expression levels and young adult asthma were consistent
with the relationships between cord-blood expression levels and infant wheeze.
Taken together, these analyses culminated in the discovery of novel genes (HK1
and LITAF) that were under differential epigenetic regulation in young adults with
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asthma, and whose expression levels in cord blood were predictive of infant wheeze. Upregulation of HK1 and down-regulation of LITAF in cord blood were associated with
increased risk of wheeze within the first year of life. Despite wheeze-predictive
expression patterns for HK1 and LITAF being present at birth, the establishment of DNAM within HK1 and LITAF appear to occur prenatally and after birth, respectively. These
findings provide a direct link between our observations in Aim 1 and Aim 3, that
increased HK1 and decreased LITAF expression increases the risk of wheeze and/or
asthma, apparently independent of age.
Not only did the findings for HK1 and LITAF from Aim 1 and Aim 3 complement
each other, but they were consistent with plausible biological links to wheeze and asthma.
Previous research as shown that up-regulation of HK172,132 and down-regulation of
LITAF140,141 can induce delayed apoptosis of some cells and it is well recognized that
apoptotic-resistant pro-inflammatory cells produce prolonged inflammation133. Thus high
levels of HK1 and low levels of LITAF in cord blood may produce, or be representative
of, cells that are more resistant to apoptotic signaling, putting those infants at greater risk
for wheeze illness within the first year of life. Given that these genes appear to be
involved in wheeze and asthma in both infants and young adults, future studies should
investigate whether cord blood expression patterns of HK1 and LITAF can improve upon
current techniques for predicting which infants with wheeze will later be diagnosed with
asthma, such as the modified asthma predictive index (mAPI)116. Improvement of such
algorithms could allow for better prospective management of wheeze in infants and
children. The discovery of these genes also provides new targets to study for potential
therapeutic or preventive techniques.
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Another innovation from Aim 1 of this dissertation was the use of recursive
random forest (RF) as a data-reduction technique for an epigenome-wide dataset. High
dimensional feature selection techniques are necessary for analyzing such large datasets
as they compress these data into more manageable subsets143. RF has been utilized in
multiple GWAS, but only infrequently utilized recursively58,144–146 and to our knowledge
only implemented with large-scale epigenetic data in a few previous investigations of
atopy62 and eczema147 in the IOW birth cohort. Also, despite the recommendation of Leo
Brieman, the original author of RF60 to test multiple values for mtry and ntree then to
pick the ‘best’ one63, many previous studies with RF simply utilized the default values. In
our analyses, we found that altering the default values of ntree, mtry, and sampsize, were
critical to stable selection of predictors from data-reduction process, emphasizing the
need to carefully evaluate such parameters when implementing the RF algorithm, at least
when used recursively for variable selection.
Summary of Findings and Innovations (Aim 2):
We explored whether persons with more homogenous wheeze-illness would share
similar genetic and/or epigenetic variations within asthma candidate genes (IL4, IL4R,
IL13, STAT6, and GATA3) from the Th2-path. From this study, we found that DNA-M at
cg25630514 in the body of GATA3 and at cg25368824 in the TSS200 of IL4
significantly varied based on different clinical characteristics among persons with
wheeze, suggesting that epigenetic regulation of these cytokines differs among persons
with wheeze or asthma that have different clinical characteristics.
To our knowledge, no one has investigated whether combinations of genetic and
epigenetic features within the Th2 pathway, one of the most heavily studied sets of genes
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in asthma research, can distinguish between complex manifestations of asthma, such as
those represented by the wheeze-illness clusters identified in the IOW birth cohort4.
Multiple recent studies have used clustering techniques to identify groups of asthmatics
that share similar physiologic or symptomatic characteristics90–92, though none of those
studies have attempted to relate such clusters to genetic or epigenetic variations. Thus,
the primary innovation from Aim 2 was that epigenetic variations, and likely other
molecular mechanisms, differed in their association with complex wheeze phenotypes.
Most interesting was cluster C4, characterized by being mostly female, late-onset
wheeze with low prevalence of allergic diseases and low levels for BDR, FeNO and
serum IgE, which differed substantially from the other clusters across many epigenetic
loci. Assuming that epigenetic regulation of expression at the nominally significant CpG
sites follows the same paradigm discussed above32, then we would expect persons in this
cluster (C4) to have lower expression of IL4, higher expression of IL13, and lower
expression of GATA3, which may be an indicator of IL13 expression from non-Th2
cells99, though further human studies are needed to clarify the differential expression and
activity of IL4 and IL13. Overall, these findings suggest that the underlying epigenetic
profiles for wheeze-illnesses differ based on a multitude of characteristics, and emphasize
the need to thoroughly characterize multiple symptoms and physiologic components of
asthma to effectively compare asthma findings across different studies and different
populations. However, given the exploratory nature and small sample size of this study,
further studies are necessary to confirm our observed findings.
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Final Remarks:
Advancements in epigenetic epidemiology are crucial to furthering our
understanding of asthma etiology. With this dissertation we identified novel epigenetic
and genetic loci that may clarify some of the underlying mechanisms involved in asthma
etiology and observed differential directions of association in Th2 genes based on young
adult wheeze clusters. Of particular note were the findings that high levels of HK1
expression and low levels of LITAF expression increased the risk of wheeze/asthma in
infants and young adults, and that DNA-M may regulate, or act as markers of, the activity
of these genes. Based on current knowledge of HK1 and LITAF, the observed expression
and/or DNA-M patterns may increase resistance to apoptotic signaling among proinflammatory cells, though further functional research is needed to clarify such
mechanisms. These genes offer promise as potential markers of asthma and wheeze, and
could be investigated in future studies as targets for therapy or for inclusion into
algorithms, such as the asthma predictive index, for predicting later-life-asthma from
early-childhood characteristics. We also found that complex wheeze clusters differed in
their epigenetic patterns within the Th2 path, suggesting that future studies of asthma
carefully evaluate what symptomatic and physiologic traits are represented within their
asthma cases when attempting to generalize findings or to conduct validation studies.
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